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ABSTRACT 
 
Bryan C. Quach: Computational approaches to studying gene regulation using chromatin 
accessibility and gene expression assays 
(Under the direction of Terrence Furey) 
 
The completion of the Human Genome Project marked the beginning of a new era in 
genomics characterized by significant improvements in high-throughput sequencing technology 
and the development of new sequencing-based assays to study a wide array of functional elements 
and biological properties at the genome-wide scale.  These advancements were accompanied by the 
formation of large, multi-institutional consortia that produced publicly available data sets and 
functional genomic studies that broadened our understanding of the genome. Previously 
uncharacterized genomic regions became recognized as important components of gene regulation, 
but the broader knowledgebase of regulatory elements raised new questions to elucidate the 
growing complexity of gene regulation models. Additionally, quantitative trait loci (QTL) mapping 
approaches began taking advantage of quantitative sequencing data to study the impacts of genetic 
variation on molecular phenotypes such as gene expression at the genome-wide level. The 
popularity of high-throughput methods for studying gene regulation and transcription lead to a 
data deluge that necessitated new statistical methods and bioinformatics solutions for data 
management, processing, analysis, visualization, and interpretation.  Specialized research areas 
emerged to better glean insights from sequencing data leading to new challenges and questions. In 
the following chapters, I present a novel machine learning framework for genomic footprinting, a 
concept focused on identifying transcription factor (TF) binding sites using chromatin accessibility 
sequencing data. I demonstrate that my framework outperforms existing methods for classifying TF 
iv 
 
binding sites via footprinting. In addition, I investigate characteristics of TF binding sites within 
chromatin accessibility data and assess technical factors that influence footprinting to provide an 
improved understanding of the strengths and limitations of using these data for TF binding site 
prediction. Through a separate study, I investigate the impact of a genotoxic chemical 1,3-butadiene 
on chromatin accessibility and gene expression in a population of genetically diverse mice. I 
perform expression QTL (eQTL) and chromatin accessibility QTL (cQTL) mapping in these mice and 
detect eQTLs and cQTLs in each tissue. In all, the work herein demonstrates multiple computational 
approaches to studying various gene regulatory relationships and provides insight on the efficacy of 
these approaches to inform future studies.  
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CHAPTER I 
Introduction 
 
 The importance of gene regulation in cell development and biological homeostasis of living 
organisms has been well recognized [1–4]. Through the Human Genome Project [5], technological 
innovations and a broader understanding of genome organization and composition paved way for 
large-scale efforts in the genomics community to better understand functional genomic elements and 
the role of non-coding DNA in transcriptional regulation [6,7]. Although these efforts improved 
understanding of gene regulatory components such as promoters, enhancers, silencers, chromatin 
structure, and transcription factors, they also increased awareness of the complexity of regulatory 
dynamics and the interactions between the various components. Furthermore, follow-up studies to 
quantitative trait loci (QTL) mapping and genome-wide association (GWA) studies that detect trait-
associated genetic variation contributed another layer of regulatory complexity by characterizing 
relationships between genetic variation and regulatory changes as intermediate mechanistic links 
between DNA sequence and phenotype [4,8]. The increasing availability of information, resources, 
methodologies, and technologies for studying gene regulation highlighted a growing opportunity and 
significance in further identifying regulatory elements and studying their roles in condition-specific 
contexts. 
 
IDENTIFYING REGULATORY ELEMENTS GENOME-WIDE WITH HIGH-THROUGHPUT ASSAYS 
Since the advent of Sanger sequencing, DNA sequencing technology continued to improve, 
and the introduction of massively parallel “next-generation” sequencing approaches revolutionized 
biological and biomedical science research by enabling the development of higher-throughput and 
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more cost-effective alternatives to microarrays to assay biological properties such as transcription, 
nucleosome occupancy, chromatin interactions, transcription factor (TF) binding, and histone 
modifications genome-wide [9]. Although multiple different next-generation sequencing platforms 
exist, they share some commonalities in their approach. Each technology first requires the 
preparation of a sequence library through the ligation of oligonucleotide adapters to the ends of the 
DNA fragments to be sequenced. The fragments are then amplified and undergo a platform-specific 
sequencing reaction that allows the classification of each nucleotide. The ability for these reactions 
to occur simultaneously leads to the high-throughput that makes them massively parallel. The 
nucleotide readouts, referred to as reads, generate large quantities of data that then require the 
application of bioinformatics approaches for downstream processing, analysis, and interpretation. 
These next-generation sequencing platforms remain widely used, however newer sequencing 
platforms are being developed such as nanopore sequencing that rely on different sequencing 
chemistry and do not require fragment amplification [10].  
From a simplified perspective, sequencing platforms all share the goal of accurately 
classifying the nucleotide sequence of the given fragments. The major distinctions in the 
sequencing-based methods for assaying different biological properties occur in isolating the 
relevant DNA or RNA. For example, Chromatin Immunoprecipitation Sequencing (ChIP-seq) aims to 
detect genomic locations of TF occupancy or histone modifications. To do this, binding proteins and 
genomic DNA are cross-linked, then the DNA is fragmented. Immunoprecipitation with a protein-
specific antibody retrieves the protein-bound sequences that are then sequenced. Enrichment of 
reads mapping to a particular genomic location indicates TF occupancy (or histone modification) 
[11]. In DNaseI sequencing (DNase-seq), chromatin accessibility is assayed using the exonuclease 
DNaseI. Exposing genomic DNA to DNaseI results in the enzyme preferentially cutting DNA in more 
accessible, nucleosome-depleted regions. Following DNaseI digestion, size selected DNA fragments 
are sequenced and genomic regions with enrichment of mapped reads are classified as accessible 
3 
 
chromatin regions [12]. In both ChIP-seq and DNase-seq, the biomolecule initially being isolated is 
DNA. With RNA sequencing (RNA-seq), RNA transcripts are initially isolated as opposed to DNA. For 
compatibility with sequencing platforms, these transcripts are typically converted to cDNA before 
sequencing, although some direct RNA sequencing approaches exist [13]. The reads from RNA-seq 
are mapped to their originating genes and can be analyzed to deduce estimates of RNA abundance.  
With the three aforementioned methods, the diversity of biological properties related to 
gene regulation that can now be studied genome-wide created new opportunities for 
understanding their interactivity. ChIP-seq, DNase-seq, and RNA-seq among other methods were 
utilized by the Encyclopedia Of DNA Elements (ENCODE) project which sought to characterize all of 
the functional elements in the human genome [7] and in later stages also included the mouse 
genome [14]. In a 2012 report, the ENCODE project had produced 1,640 data sets in 147 different 
human cell types [15], and a 2014 mouse ENCODE publication comparing the mouse and human 
functional elements reported over 1,000 data sets in 123 mouse cell types and primary tissues [14].  
Analyses by the ENCODE consortium found that 80.4% of the human genome is covered by at least 
one functional element. Of this fraction, RNA-associated elements and histone modifications 
comprised a large majority, and 15.2% of the coverage was attributed to DNaseI hypersensitive 
sites [15]. In comparisons with mouse functional elements, chromatin state landscapes and TF 
networks were found to be relatively stable between human and mouse [14]. Additionally, gene 
expression profiles were shown to be more consistent within tissue than within species [16]. To 
build upon the work by the ENCODE project, the more recent Roadmap Epigenomics Project 
constructed a collection of epigenomic profiles for 127 human tissues and cell types from adult and 
embryonic samples [17]. Analyses of these data showed associations between proximal and distal 
regulatory regions, histone marks, DNA methylation, chromatin accessibility, spatial organization, 
and gene expression that play important roles in cell type identity, development, and disease [17].  
Taken together, the catalogue of genomic and epigenomic data and integrative analyses from these 
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large-scale projects contributed new insights into the organization and regulation of human and 
mouse genes and the genome and continues to serve as an expansive public resource for biomedical 
research. 
 
GENE EXPRESSION AND CHROMATIN ACCESSIBILITY AS QUANTITATIVE TRAITS 
 A fundamental challenge in genetics research is to understand genetic variation and its 
relationship to phenotypic variability. Efforts such as the International HapMap and 1000 Genomes 
Project extensively characterized common genetic variation across diverse human populations 
[18,19], and GWA studies have leveraged advancements in genotyping technology to link genetic 
variants to human traits and diseases. Although informative in many regards, these studies do not 
resolve the underlying biological mechanisms of discovered genotype-phenotype associations. For 
functional follow-up, data produced by the ENCODE and Roadmap Epigenomics consortia have 
served as valuable resources to refine lists of candidate GWAS variants and identify putative roles 
of non-coding variants [20], but these data still do not directly assess the impact of inter-individual 
variation on gene regulation and cellular behavior that results in the observed phenotypes. 
A related but distinct approach from GWAS is expression QTL (eQTL) mapping. In eQTL 
mapping, gene expression levels are treated as quantitative traits and tested for associations with 
genetic variants. The first reported eQTL study analyzed over 1,500 genes and 3,312 genetic 
markers between two strains of Saccharomyces cerevisiae [21]. Since then, eQTL mapping has been 
performed in various contexts using model organisms and humans [22–24]. With RNA-seq (or gene 
expression microarrays) and current genotyping approaches, these analyses can include tens of 
thousands of genes, each regarded as an independent quantitative molecular phenotype. The 
Genotype-Tissue Expression (GTEx) Project pilot analysis demonstrated the utility of eQTL 
analyses by performing eQTL mapping in 9 human tissues and identifying eQTLs shared and unique 
to each. Significant eQTLs were compared to GWAS disease-related single nucleotide 
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polymorphisms (SNPs) showing whole-blood specific eQTL enrichment for autoimmune-related 
GWAS variants [24]. This showed that by directly modeling the relationship between genetic 
variation and gene expression, eQTL mapping serves as a powerful tool to gain more insight into 
gene regulatory changes that can then be used to elucidate other genotype-phenotype links. 
As a complementary approach to eQTL mapping, the genetic underpinnings of chromatin 
variation have been studied using sequencing-based assays. Kasowski et al. observed variation 
between lymphoblastoid cell lines (LCLs) from 19 individuals for histone modifications H3K27ac, 
H3K4me1, H3K4me3, H3K36me3, and H3K27me3. Work by McVicker et al. further assessed the 
genetic relationship to histone modifications by identifying SNPs significantly associated with 
variation of histone mark signals in LCLs derived from 10 unrelated individuals [25]. Similarly, 
Degner et al., used DNase-seq to measure chromatin accessibility in 70 LCLs and detected 8,902 
chromatin regions where chromatin accessibility was significantly associated with genotype, which 
they referred to as DNaseI sensitivity QTLs (dsQTLs). The dsQTLs discovered were found to be pre-
dominantly local with enrichments for predicted TF binding sites. Sixteen percent of dsQTLs were 
also classified as eQTLs, and 55% of identified eQTLs were also dsQTLs. More recently, another 
genome-wide chromatin accessibility assay was developed called Assay for Transposase-Accessible 
Chromatin Using Sequencing (ATAC-seq) which relies on the Tn5 “tagmentation” process to 
fragment DNA at accessible chromatin regions and append adapters for sequencing [26]. Using 
ATAC-seq and genotype data from 24 European individuals, Kumasaka et al. reported 2,707 
chromatin accessibility QTLs (cQTLs) which were also enriched for eQTLs and dsQTLs [27]. These 
QTL analyses using histone marks and chromatin accessibility data as quantitative traits 
demonstrate how chromatin assays can contribute to discovering associations between genotype 
and gene regulation that can ultimately inform physiologic or disease phenotype-genotype 
associations. 
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THE COLLABORATIVE CROSS AS A RESOURCE FOR GENETICS STUDIES 
 In human genetics and genomics studies, certain constraints limit the possible experimental 
designs that can be practically realized. As a proxy, various species such as Danio rerio (zebrafish), 
Drosophila melanogaster (fruit fly), and mus musculus (mouse) have been studied as model 
organisms to infer aspects of human biology [28–30]. In a 2002 review, Threadgrill et al. outlined 
propositions made by the Complex Trait Consortium to develop a mouse genetics resource for 
effective study of complex traits using QTL approaches [31]. The design and implementation of 
creating this resource became known as the Collaborative Cross (CC) [32]. The CC involved an 
international, multi-institutional effort to create a multiparent panel of recombinant inbred mouse 
strains derived from five classical inbred strains (A/J, C57BL/6J, 129S1/SvImJ, NOD/ShiLtJ, and 
NZO/HlLtJ) and three wild-derived strains (CAST/EiJ, PWK/PhJ, and WSB/EiJ) denoted as 
“founders”. Because CC strains are inbred, they provide an advantage over human studies in that 
each strain can produce genetically identical individuals. This reduces the genotyping burden and 
allows for more sophisticated experimental designs to study multiple variables within the same 
population. 
As described in [32], creating a CC strain requires a funnel breeding scheme that begins 
with the mating of the 8 founder strains in pairs. Two pairs from the resulting generation are then 
mated, and this process continues for subsequent generations until a final inbred CC strain is 
produced. By permuting the pairs in the initial generations, a large number of strains can be 
constructed. In an evaluation of the genome architecture of 350 CC strains, similar founder 
haplotype representation was observed when averaged across the CC lines, but deviations from 
expected frequencies were noted when focusing on specific genomic regions. Unlike many classical 
inbred strains, the CC population did not exhibit high levels of long-range linkage disequilibrium 
(LD). This type of LD has been reported to increase false positives in association mapping studies 
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[33]. As a proof-of-concept, Aylor et al. performed eQTL mapping using 156 incipient inbred CC 
lines (pre-CC) and detected 7,235 liver eQTLs at less than 1 megabase (Mb) resolution. A QTL study 
by Kelada et al. used 131 pre-CC lines to identify genetic associations with blood cell volume, white 
blood cell count, percentage of neutrophils, and monocyte number [34]. More recently, 45 CC 
strains were used to identify liver eQTLs and QTLs associated with treatment response to the drug 
tolvaptan. The study showed strain-specific variability in liver toxicity phenotypes and found 
several candidate susceptibility genes for tolvaptan drug-induced liver injury [35]. Each of these 
studies demonstrates the feasibility and power of the CC as a resource for QTL mapping and 
interrogating genetic factors in disease and complex traits. 
The significant advancements in systems genetics and functional genomics have made the 
intricacies of gene regulation more apparent, fostering new hypotheses for how the contributing 
components interact [3,36,37]. The development of sequencing-based assays such as those used by 
ENCODE and the Roadmap Epigenomics Project made new types of analyses possible, but in doing 
so exposed new questions and challenges to address. Among these challenges is the development of 
bioinformatics approaches and statistical methods to manage, process, analyze, and interpret the 
vast quantities of biological data being generated. For instance, the development of DNase-seq and 
ATAC-seq for detecting accessible chromatin also led to observations that these methods could 
probe TF binding locations through an approach called footprinting [26,38], but the strengths and 
weaknesses of footprinting have not been well characterized. As previously mentioned, the utility of 
the Collaborative Cross for QTL mapping has been demonstrated, but the advantages of the CC can 
be further demonstrated by experimental designs and analyses that interrogate both chromatin 
accessibility and gene expression under varying environmental conditions. 
In chapter II, I introduce a novel method for TF binding site prediction, Detecting Footprints 
Containing Motifs (DeFCoM), that integrates DNase-seq or ATAC-seq data with ChIP-seq data and 
TF sequence motifs [39]. I use ENCODE data in conjunction with TF motif predictions to compare 
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DeFCoM to existing approaches and show that it outperforms other methods. I also evaluate 
current assumptions about chromatin accessibility signal characteristics at TF binding sites and 
assess the impact of technical factors on footprinting. In chapter III, I present an unpublished 
analysis that compares lung, liver, and kidney gene expression and chromatin accessibility for a 
control group of CC mice and mice exposed to the chemical 1,3-butadiene. I also characterize eQTLs 
and cQTLs in the three tissues to provide a basis for further studies investigating genetic 
associations with gene expression and chromatin accessibility in the CC population. In chapter IV, I 
discuss how my findings in Chapter II contribute to evaluating footprinting and integrating it into 
gene regulation studies, and I conclude the chapter discussing the significance of how my findings 
in analyzing CC mice contribute to interrogating environmental exposure and gene regulation in 
future CC studies. 
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CHAPTER II 
DeFCoM: analysis and modeling of transcription factor  
binding sites using a motif-centric genomic footprinter1 
 
OVERVIEW 
Identifying the locations of transcription factor binding sites is critical for understanding 
how gene transcription is regulated across different cell types and conditions. Chromatin 
accessibility experiments such as DNaseI sequencing (DNase-seq) and Assay for Transposase 
Accessible Chromatin sequencing (ATAC-seq) produce genome-wide data that include distinct 
“footprint” patterns at binding sites. Nearly all existing computational methods to detect footprints 
from these data assume that footprint signals are highly homogeneous across footprint sites. 
Additionally, a comprehensive and systematic comparison of footprinting methods for specifically 
identifying which motif sites for a specific factor are bound has not been performed.  
Using DNase-seq data from the ENCODE project, I show that a large degree of previously 
uncharacterized site-to-site variability exists in footprint signal across motif sites for a 
transcription factor. To model this heterogeneity in the data, I introduce a novel, supervised 
learning footprinter called DeFCoM (Detecting Footprints Containing Motifs). I compare DeFCoM to 
nine existing methods using evaluation sets from four human cell-lines and eighteen transcription 
factors and show that DeFCoM outperforms current methods in determining bound and unbound 
                                                          
 
 
1 A version of this work was previously published as Quach B, Furey TS. DeFCoM: analysis and 
modeling of transcription factor binding sites using a motif-centric genomic footprinter. 
Bioinformatics. 2016;33: btw740.  
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motif sites. I also analyze the impact of several biological and technical factors on the quality of 
footprint predictions to highlight important considerations when conducting footprint analyses and 
assessing the performance of footprint prediction methods. Lastly, I show that DeFCoM can detect 
footprints using ATAC-seq data with similar accuracy as when using DNase-seq data. 
 
INTRODUCTION 
Chromatin dynamics vary based on developmental stage [40], cell type [41], and 
environmental stress [42]. Transcription factors (TFs) bind DNA in regions of accessible chromatin 
and play a central role in pre-transcriptional gene regulation. Understanding these interactions is 
critical in deciphering transcriptional regulation that defines cell identity in different contexts. 
DNase-seq [12] and ChIP-seq [43] identify regions of accessible chromatin and TF binding genome-
wide, respectively. Notably, Hesselberth et al. observed that DNase-seq produces “footprints” at 
active TF binding sites characterized by a relative depletion of DNase-seq signal at these sites [44]. 
Thus, a single DNase-seq experiment captures high-resolution TF binding information for many 
TFs. As performing ChIP-seq for multiple TFs quickly becomes cost prohibitive, DNase-seq 
footprinting offers an enticing alternative.  
Several computational footprint identification methods, which I will refer to as 
“footprinters”, have been developed [38,45–53]. These footprinters embrace one of two 
philosophies, which I denote as de novo and motif-centric footprinting (see Table 2.1 for an 
overview of methods). Models generated by de novo footprinters assume that there exist general 
data characteristics at footprint sites. These TF-agnostic models are used to predict all footprint 
sites, and then motif databases are queried to determine potential TFs bound in each individual 
footprint. In contrast, motif-centric footprinters first generate a set of candidate TF binding sites 
(TFBSs) based on a motif, and then predict at which motif sites a footprint exists, indicating active 
binding. Within each group, current methods exhibit similarities in approach. For instance, the de 
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novo footprinters DBFP, HINT, and the HMM-based method described in [38] model footprints 
using probabilistic graphical models with similar state representations. FOS, Wellington, and 
DNase2TF are de novo footprinters that search for genomic locations akin to short inverse peaks. 
The motif-centric footprinters CENTIPEDE, msCentipede, and FLR utilize two-component mixture 
models to represent bound and unbound sites. In addition to DNase-seq data, some methods allow 
for the integration of complementary information such as histone modification status or distance 
from the nearest transcription start site. All these methods implicitly or explicitly assume there 
exists two distinct signal patterns in DNase-seq data that distinguish TF-bound and unbound sites. 
Except for msCentipede, footprinters expect that DNase-seq signal is highly homogeneous in both 
the bound and unbound groups and thus can be represented by a single model. This assumes TFs 
bind DNA in the same manner genome-wide, but TF binding behavior can vary across TFBSs [54]. 
More recently, Kahara and Lahdesmaki proposed a supervised classification approach, 
BinDNase, that learns TF-specific DNaseI cleavage patterns from training data to predict footprints 
in other data [46]. They show that their supervised approach often produced superior prediction 
accuracy over two unsupervised generative models, PIQ and CENTIPEDE. In contrast, Gusmao et al. 
conducted a systematic footprinter comparison and found most generative model footprinters 
outperformed BinDNase [55]. In their analysis, footprint detection accuracy was evaluated within a 
de novo footprinting framework based on overlap with ChIP-seq peak annotations. It is not clear 
how accurately this evaluates motif-centric footprinter performance.  
Here, I conducted an in-depth, motif-centered analysis of DNaseI digestion signals and 
DNase-seq footprinters to provide a more complete understanding of strengths and weaknesses of 
current methods. I introduce a novel motif-centered method, Detecting Footprints Containing 
Motifs (DeFCoM), that approaches footprint identification using a nonlinear supervised 
classification framework. Importantly, DeFCoM is designed to capture variation in DNaseI signal 
within active footprints and unbound motif sites to enhance footprint classification accuracy, a 
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consideration unaccounted for in previous footprinters. I compared the performance of DeFCoM 
against both de novo and motif-centric footprinting approaches across eighteen TFs in four cell-
lines using data from the Encyclopedia of DNA Elements (ENCODE) Project [7] and show that 
DeFCoM outperforms existing approaches overall. In addition, I analyzed the variability in accuracy 
across multiple TFs and the effect of data quality and DNase-seq sequencing depth. Lastly, I show 
DeFCoM can detect footprints in data from Assay for Transposase-Accessible Chromatin sequencing 
(ATAC-seq) experiments with similar classification accuracy as with DNase-seq data 
 
MATERIALS AND METHODS 
Data and software 
DNase-seq and ChIP-seq data (Tables 2.2 and 2.3) were obtained from the UCSC (University 
of California at Santa Cruz) ENCODE portal (https://www.genome.ucsc.edu/ENCODE/). ATAC-seq 
data for GM12878 [26] was obtained from GEO (Gene Expression Omnibus) using identification 
code GSE47753. The DAC Blacklisted Regions and Duke Excluded Regions for hg19 were 
downloaded from the UCSC Genome Database then combined into one set. 
DeFCoM utilizes the Python packages PySam v0.9.0 and scikit-learn v0.17 [56]. The R 
package ROCR [57] was used for computing performance statistics and the ROC curves for the 
footprinters. F-Seq [58] was used to call peaks for DNaseI hypersensitive sites. 
 
Generating cell-line specific motif sites 
Sets of motifs labeled as active (TF-bound) or inactive (TF-absent) were generated as 
follows: 1) Transcription factor motif position weight matrices were downloaded from 
http://compbio.mit.edu/encode-motifs/ [59]. Motif occurrences were identified across the hg19 
genome using FIMO (MEME v4.9.0) [60] with a genomic  background nucleotide distribution pre-
computed by FIMO and the parameters “--max-strand --max-stored-scores 1000000 --no-qvalue”. 
13 
 
2) Predicted motif sites were removed if (i) they fell in ENCODE blacklisted regions, (ii) less than 
10% of bases within a 200 bp window centered on the motif center had DNase-seq digestion data; 
(iii) they were less than 400 bp from chromosome boundaries; or (iv) there were ambiguous 
nucleotide calls within 400 bp of the motif site center. 3) Motif sites were annotated as active if they 
overlapped ChIP-seq peaks for that TF, or else they were labeled inactive. If multiple motif sites 
overlap the same peak region, only the site closest to the annotated point-source of the peak was 
retained. To further ensure inactive sites were not bound, I calculated ChIP-seq and input control 
signal enrichments, defined as sTF - scontrol, where sTF and scontrol are sequencing-depth normalized 
read density values in 200 bp windows centered on the motif. Inactive sites where sTF - scontrol > 0 
were removed. Motif sets were created for 18 TFs (CEBPB, CHD2, CTCF, EP300, GABPA, JUN-D, 
MAFK, MAX, MYC, NRF1, RAD21, REST, RFX5, SRF, SP1, TAF1, TBP, USF2) in 4 human cell-lines 
(GM12878, H1-hESC, HepG2, and K562) except SP1 in K562 (no data). 
 
Computing aggregate DNaseI digestion profiles 
To create TF-specific summary statistics for each class of motif sites, I first generate the 
active and inactive motif site sets as detailed above. If multiple motifs exist for a TF, only one was 
chosen. For each class of motif sites, I constructed a matrix of DNaseI digestion frequencies where 
each row represents a unique motif site in the genome and each column represents a position 
within or flanking a motif site. All the rows were aligned based on the center of the motif site. 
DNaseI cut frequencies are denoted in DNase-seq data as the number of 5’ read ends aligning at a 
given genomic position. To remove motif sites with spurious spikes in DNaseI activity, any rows of 
the matrix with a value exceeding 500 were removed. From these matrices all summary statistics 
were computed per column. For the aggregate DNaseI cut profiles, I used calculated mean cut 
frequencies. Likewise, per-column mean and standard deviations were computed to obtain 
coefficients of variation values. 
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DNaseI signal profiles and correlations 
Aggregate DNaseI signal profiles were calculated for active and inactive motif sites for each 
TF in each cell type. DNaseI signal correlations for NRF1 were performed using only sites 
corresponding to the PWM (position weight matrix) “disc_1”, for CHD2 using motif “disc_1”, and for 
CEBPB using motif “known_1” (Figure 2.1) to ensure variability was not due to multiple motifs. 
Motif sites were extended 50 bp from the motif center and signal profiles were calculated. To 
remove sites with spurious spikes in DNaseI activity, motif regions with more than 500 DNase-seq 
reads were removed. Profiles were smoothed using 7 bp sliding windows to improve signal quality 
at sites with sparse signal. Aggregate mean DNaseI signal profiles for active and inactive sites were 
created using smoothed individual profiles. Pairwise Pearson correlation coefficients between 
active and inactive motif DNaseI profiles were used for complete-linkage hierarchical clustering 
followed by heatmap visualization.  
 
DeFCoM feature extraction and training 
DeFCoM (Detecting Footprints Containing Motifs) is an SVM (support vector machine)-
based [61] supervised footprinter . Given a set of motif sites labeled as active or inactive for a given 
TF in a cell type/experimental condition, the SVM classifier is trained on features that are derived 
from DNase-seq data from the same cell type for each motif site. The trained model is used to 
predict active and inactive sites in a test set based only on DNase-seq data. 
To train DeFCoM, motif site sets of size m and n, labeled as active or inactive respectively, 
were generated as described above (see Generating cell-line specific motif sites). The 5’ end of each 
DNase-seq read was considered a digestion site. Initial active and inactive motif site DNaseI 
digestion count matrices, DActivems and DInactivens,, were calculated, in which each row corresponded to 
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a scaled DNaseI digestion profile consisting of the square root of the DNaseI digestion frequency at 
each position in an s-sized region centered on a motif site. For all the training and evaluation tests, 
s=200 bp regions were used. To account for spurious spikes in the data, any row in the matrix with 
a value greater than √500 was removed. 
Intuitively, I wished to generate DNase digestion features in windows around a motif site, 
with smaller windows used near the motif site where the TF binds to allow for greater resolution, 
and progressively larger windows used at more distant regions. I also wanted to account for sparse 
or noisy DNaseI data.  Given the region size s, I first defined varying-sized, non-overlapping, 
contiguous windows symmetric about the motif site center. Let x∈{0,1,2,...,k} index each window 
starting at the motif site center with the windows progressively increasing in size from 0 to k. I 
define f(x), the size of window x, to be 
  (1) 
  (2) 
where the recursive function g(x) equals the sum total size of all windows up to and including 
window x. The total number of windows k that will span a region of size s/2 can be calculated as 
follows: 
  (3) 
In equations 1 and 3, I use s/2 because windows are symmetric about the motif center. For s=200, I 
defined 12 windows (6 on each side of the motif site center) with sizes 45, 21, 14, 9, 6, 5, 5, 6, 9, 14, 
21, and 45. For each window, I computed the mean of the scaled DNaseI digestion counts and the 
slope of these counts across the window using DActive and DInactive.  This generated a feature vector f of 
length 4k. To provide additional global features of the region s, I partitioned a 90 bp segment 
centered on the motif center into 3 windows, computed the mean and slope for these windows (6 
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features total), and calculated the mean cut frequency of a 150 bp region centered on the motif 
center (1 feature). Lastly, maximal absolute value scaling was used to scale each of the 4k + 7 
features to a [-1,1] range. This results in the final feature matrices FActive and FInactive. 
As part of the training process, DeFCoM selects between a linear and radial basis function 
(RBF) kernel SVM to use as the final classifier. To decide between the two SVM models, I 
bootstrapped 1000 samples 100 times from each of FActive and FInactive and applied 5-fold cross 
validation. I used the mean pAUCs (5% FPR) from the cross validations to select a model. 
Training a soft-margin SVM requires the selection of a hyperparameter, which I denote as c, 
that specifies a tolerance threshold for the number of samples from either class that lie on the 
wrong side of the separating hyperplane. The higher the value of c, the more heavily 
misclassification is penalized during model training. Additionally, the RBF kernel contains a 
parameter that I denote as γ, which determines the distance of influence of the chosen support 
vectors. Higher values of γ specify a smaller distance of influence. For both the cross validation and 
cross cell-line tests, DeFCoM performs a grid search to find the best c and γ. The values used in the 
grid search were c∈{0.01, 0.1, 1, 10, 100, 1000, 10000} and γ∈{0.00001, 0.0001, 0.001, 0.01, 0.1, 1, 
10, 100}. 
For within cell-line tests, the SVM type (linear or RBF kernel) is pre-specified based on the 
analysis being performed. I applied 5-fold nested cross validation using annotated motif sites and 
DNase-seq data for the specified cell-line, and all evaluation statistics were computed for each fold 
then averaged across folds. In the cross cell-line setting, training the final SVM for DeFCoM is a two-
stage process. First, a linear or RBF kernel SVM is chosen along with c and/or γ values.  Then, a 
subset of 3000 samples from each class is chosen to train the selected SVM model. Because the 
number of total samples typically is much larger than these subsets, I select the SVM type and the c 
and γ values using a bootstrapping procedure. I take 1000 random samples from each motif site 
class 100 times, and for each bootstrap iteration, I apply 5-fold cross validation to both a linear and 
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RBF kernel SVM using the aforementioned grid of c and/or γ values. Following the bootstrapping, I 
compare the distributions of pAUCs generated by each SVM type using a two-sided Student’s t-test. 
I selected the RBF kernel when there was a statistically significant difference (α ≤ 0.01) and the 
linear SVM otherwise. Following SVM type selection, I chose final c and/or γ values based on which 
values were selected the most frequently during the bootstrap procedure for the selected SVM type. 
To improve the computational efficiency of the SVM training phase, the chosen SVM was trained 
with 3000 randomly selected samples from each of FActive and FInactive to produce the final trained 
model. 
For ATAC-seq data, the DActive and DInactive matrices were constructed using Tn5 transposase 
tagmentation events as opposed to DNaseI digestion frequencies. Tn5 tagmentation sites are 
denoted as 5’ ATAC-seq read ends offset 5 bp downstream on the positive DNA strand and 4 bp 
upstream on the negative strand. 
 
Footprinter implementations for comparative analysis 
The footprinters BinDNase, CENTIPEDE, cut density, DNase2TF, HINT, FOS, msCentipede, 
PIQ, and Wellington (Table 2.1) were used to evaluate DeFCoM. These methods were chosen based 
on availability, compatibility with my evaluation framework, and their broad range of conceptually 
diverse approaches to footprinting. I outline below how these methods were applied in a motif-
centric evaluation framework. Any footprinter not listed was applied with no modifications and 
default settings. 
BinDNase 
Similar to DeFCoM, BinDNase is a supervised footprinter. For the training phase of 
BinDNase, 3000 samples from each class of motif sites were randomly chosen. The remaining 
parameters were the same as described in [46].   
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CENTIPEDE 
In implementing CENTIPEDE I used the default parameters specified by [50] with the 
exception that the prior included only PWM scores.  
Cut Density 
Cut density serves as a straightforward “baseline” model for footprinting. It simply sums the 
number of DNase-seq 5’ read ends that map within a specified genomic region. For each motif site 
in the evaluation sets, cut density was computed for regions spanning 50 bp upstream and 
downstream of the motif site center. 
DNase2TF 
We ran DNase2TF on motif sites that were extended by 100 bp in both directions to obtain 
an initial list of footprint calls. The “FDRs” parameter was set to 1 with default values for the other 
parameters. I filtered the footprints to only those that overlapped at least 75% of a motif site. If the 
footprint region is smaller than the motif site, then it was also retained regardless of percent 
overlap. For each motif site, I assigned it the score from the overlapping footprint. If multiple 
footprints correspond to a motif site, I selected the highest score. If no footprint is associated with 
the motif site then it was given the minimum possible score. 
HINT 
We applied HINT similarly to DNase2TF. Using default settings, an initial list of footprints 
was generated by evaluating motif sites that were extended by 100 bp in both directions. These 
were filtered to footprints smaller than their corresponding motif site and footprints overlapping at 
least 75% of a motif site. Motif sites were assigned scores using the same process as for DNase2TF. 
FOS 
FOS computes a score based on a depletion of reads within a central window of length c 
base pairs compared to a left and right flanking window each of length f base pairs. With each motif 
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site, I calculated an FOS score for all combinations of c and f where c is an integer between 6 and z 
and f∈{3,4,...,11}. Let m represent the length of a motif, then z=2*(21-m) when m is less than or 
equal to 18 and 6 otherwise. I aligned c to be centered over the motif site. I retained the highest 
score from all the calculations for a motif site. Sites FOS failed to score were given the lowest 
possible score. 
Wellington 
Similar to FOS, Wellington uses a center and flanking region to compute a score and call 
footprints. Wellington searches for footprints in a region using a combination of a 35 bp flank size 
and center sizes 11, 13, 15, 17, 19, 21, 23, and 25. I allowed Wellington to score sites using input 
regions that were 49 bp flanks from the center of the motif site. The maximum of the absolute 
values of scores was used as the footprint score for the associated motif site. 
 
Effective sequencing depth 
Signal-to-noise was measured using FRiP (fraction of reads in peaks) scores [62]. Peaks 
were called using F-Seq with default parameters, then the ratio of DNase-seq reads aligning within 
the top 50,000 peaks (ranked by F-Seq score) to the total aligned reads was calculated. This ratio 
was multiplied by the total aligned reads to obtain the effective sequencing depth. 
 
Subsampled sequencing depth analysis 
To compare DeFCoM’s performance in two cell-lines with similar effective sequencing 
depths but different signal-to-noise ratios, I applied downsampling to both GM12878 and H1-hESC 
DNase-seq data. In each cell-line I used SAMTools to downsample the data to 25, 50, 75, and 100 
million mapped reads. At each sequencing depth, I converted the labeled motif sites and DNase-seq 
data into feature vectors. I then used these feature vectors for 5-fold nested cross validation of 
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DeFCoM with the RBF kernel SVM. Lastly, the mean pAUCs (5% FPR) from the folds were computed 
for 18 transcription factors.   
 
RESULTS 
Aggregate DNaseI digestion profiles do not capture motif site heterogeneity 
Aggregate mean DNaseI digestion profiles summarize positional DNaseI cleavage 
preferences at TFBSs. These profiles convey a single value at each position, thus they lack 
information regarding the variability in DNaseI activity at a given position across sites. Raj et al. 
showed that variation in DNaseI activity at TF-bound SP1 motif sites exceeded that expected under 
a multinomial model of DNaseI digestion signal [51]. To evaluate this more broadly, I determined 
positional variability in DNaseI digestion signal for multiple TFs (Figures 2.2A and 2.3). I stratified 
motif sites into active and inactive based on presence of corresponding ChIP-seq signal for the 
factor in the same cell type. I used these to evaluate two common assumptions held by several 
footprinting methods: 1) active TFBSs possess a general footprint pattern of local depletion in 
DNaseI digestion relative to flanking regions; and 2) inactive motif sites contain approximately 
uniformly distributed DNaseI digestion signal. For most factors, aggregate profiles for active sites 
clearly produced expected DNaseI digestion patterns, but with relatively large standard deviations. 
An investigation of individual binding sites clearly shows how sites deviate from the aggregate 
pattern (Figures 2.2C and 2.2D).  In some cases, the previously characterized sequence preferences 
for DNaseI digestion [63] are visually apparent. For a minority of the TFs, the aggregate profile for 
active sites portrays a visually weak footprint or none at all (i.e. SRF, Figure 2.3). Overall, TFs 
exhibit aggregate profiles with consistently high coefficients of variation (Figure 2.4).  
In spite of position-specific variability across motif sites, it is possible that DNaseI signal at 
individual sites resemble the aggregate profile in shape but not scale. To quantify the similarity of 
DNaseI digestion profiles at individual sites to the aggregate mean profiles, I calculated Pearson 
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correlation coefficients between the aggregate profiles and every individual TFBS profile for 
CEBPB, CHD2, and NRF1 (Figure 2.5). Among the 3 TFs, 30-63% of the individual profiles did not 
correlate with the same class aggregate profile (Pearson’s r < 0.1). Interestingly, I found that 17-
51% of individual profiles from the active and inactive classes exhibited stronger positive 
correlations with the aggregate profile from the opposite class. 
To further assess within and between class heterogeneity, I computed Pearson correlations 
between the top 2000 individual DNaseI digestion profiles, ranked based on the number of DNase-
seq reads in a 100 bp window centered on the motif site, in the active and inactive classes for all 
three factors. I observed small clusters of highly correlated sites, implying possible subgroupings 
for DNaseI cleavage profiles within each class. I also found 34-53% of motif sites within each class 
exhibited negative or no correlation to each other (Pearson’s r < 0) (Figures 2.2D and 2.6). Notably, 
4-6% of correlations between sites from opposite classes had Pearson’s r > 0.5. These analyses of 
variability in DNaseI digestion signal strongly indicate that aggregate mean profiles do not 
sufficiently capture the heterogeneity in DNaseI activity across motif sites. 
We hypothesized that high correlations between sites from one class to the aggregate 
profile of the opposite class may be partially attributed to similarities in binding preferences for 
multiple TFs. Therefore, a motif site deemed inactive for a specific TF based on ChIP-seq data could 
be active for another TF with a similar motif. I assessed this by determining how many inactive 
motif sites overlapped ChIP-seq peaks for at least one other TF for each of 18 TFs in the K562 cell 
line. I found that this was the case for 8.85% of all inactive sites (Figure 2.7). For most TFs, the 
number of inactive motif sites was significantly larger than the number of active sites (Table 2.4). 
Thus, while the number of inactive sites overlapping another ChIP-seq peak was relatively small, 
these represented 0.41 to 32.21 times the total number of active motif sites for a TF. Footprint 
patterns at inactive sites that resemble active sites due to the binding of another factor highlights 
an important consideration and caveat when conducting motif-centric footprinting and evaluating 
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the accuracy of footprint predictions. This also applies to de novo footprinting as it becomes an 
issue when annotating called footprints using motifs. A potential solution would be to exclude all 
motif sites overlapping ChIP-seq peaks for multiple TFs. However, this would remove 66%-100% of 
active sites for a TF. Additionally, this would require conducting a multitude of ChIP-seq 
experiments and disregards the fact that many TFs have binding partners.  
 
Modeling data heterogeneity for footprinting 
To account for the high variance in DNaseI activity at motif sites, I devised a novel 
supervised learning based footprint prediction framework called DeFCoM (Detecting Footprints 
Containing Motifs). DeFCoM trains an SVM using extracted features from DNaseI digestion profiles 
of motif sites labeled as active or inactive. In the training phase, DeFCoM applies a model selection 
procedure to choose between a linear kernel and nonlinear RBF kernel (Figure 2.8; see Materials & 
Methods). This allows DeFCoM to capture the complexity of the data when necessary with the RBF 
kernel, while avoiding over-fitting, a common problem in supervised learning, by choosing the 
linear kernel when that complexity is lacking. Once trained, the SVM uses features from DNaseI 
digestion profiles for new, unlabeled motif sites to determine which are active and inactive in 
another cell type/condition.  
To assess DeFCoM’s classification accuracy, I first performed 5-fold nested cross validation 
on 71 evaluation sets comprised of data from 18 transcription factors in the human cell-lines 
GM12878, H1-hESC, HepG2, and K562 generated by the ENCODE project. Secondly, I tested 
DeFCoM’s ability to generalize across cell types by training models using data from one cell type 
and testing on an independent cell type. I also wanted to know whether using the RBF kernel 
increased accuracy given the demonstrated heterogeneity in these data. Therefore, for both sets of 
experiments, I used a linear and an RBF SVM and compared their classification performance. I will 
refer to these models as DeFCoM-linear and DeFCoM-RBF respectively. I calculated receiver 
23 
 
operating characteristic (ROC) Area Under the Curve (AUC) values using all the data and also partial 
AUC (pAUC) values corresponding to partial ROC curves at a 5% false positive rate (FPR) cutoff.  
When applied to the 71 data sets, DeFCoM-RBF performed better than a random classifier in 
all cases (Figure 2.9A). Notably, I observed a wide distribution of pAUC scores ranging from 0.096 
to 0.981, but there was less variability in the full AUC scores (0.714-0.998). For the cross cell-line 
experiments, I expected that additional variability across the two data sets would decrease 
performance compared to the within cell-line cross validation tests. Indeed, I witnessed overall 
lower scores from the former but by a marginal amount (median pAUC decrease of 0.021) 
indicating there exist consistent footprint signals across cell types.  
To determine whether using the nonlinear RBF kernel to model heterogeneity was 
warranted, I repeated the above experiments using the linear kernel. Overall, DeFCoM-RBF 
improved classification accuracy for all cell-lines in both experimental setups except for the cross 
cell-line case where the test set was derived from data in the K562 cell line (Figure 2.9B). I saw that 
the pAUC increased as much as 0.141 when using DeFCoM-RBF. However, the pAUC was essentially 
the same in 31% of cross validation tests and 41% of cross cell-line tests. This demonstrates that 
the RBF kernel can provide large gains in accuracy, but some factors or data sets may not possess 
enough DNaseI signal heterogeneity to benefit from more complex footprint modeling. 
Interestingly, DeFCoM-linear performed substantially better on cross cell-line tests when 
training with GM12878 and evaluating with K562 data. This demonstrated the need for flexibility in 
model complexity. Therefore, I incorporated a model selection step during DeFCoM training to 
automatically determine the most appropriate kernel for a given test (see Materials & Methods). I 
found that with the exception of CTCF, my model selection procedure identified the better model in 
all cases in which there was a measurable difference between kernels (pAUC difference > 0.05; 
Figure 2.10). I also evaluated alternative methods for addressing cross cell-line applications of 
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DeFCoM and found the aforementioned approach produced the best results. Nevertheless, I 
describe the alternative procedures in the following section.  
 
Variations for DeFCoM training in cross cell-line applications  
To address the decrease in classification accuracy of DeFCoM when training in one cell-line 
and testing in another, I initially explored two methods in addition to the SVM model selection 
procedure. 
Mitigating Data set Shift 
Given the variety of factors involved in generating DNase-seq and ATAC-seq data as well as 
biological variability in the samples processed for sequencing, I considered the possibility that the 
DNase-seq and ATAC-seq data used for training DeFCoM may differ enough from the data being 
used during the classification phase of cross cell-line analyses to negatively impact classification 
performance. More formally, I hypothesized that the joint distribution between inputs into 
DeFCoM’s RBF kernel SVM and the outputs produced by this SVM differed between the training and 
testing stage. This phenomena is more generally referred to in machine learning literature as data 
set shift [64]. 
To account for the possibility of data set shift, I trained a logistic regression model with data 
from GM12878 and K562 to obtain for each sample the probability that the sample was derived 
from GM12878, P(GM12878), and the probability that it was derived from K562, P(K562). If more 
than 25,000 motif sites existed in the active and inactive motif site sets for both cell-lines, I 
randomly selected 25,000 samples from each of the active and inactive motif site sets, totaling to 
100,000 sites. These samples were converted into feature vectors, and assigned the class label 
“GM12878” or “K562”. The labeled feature vectors were then used to train an L2-regularized 
logistic regression model. The regression model was then applied to feature vector representations 
of all the samples in both cell-lines to obtain P(GM12878) and P(K562) for each sample. The 
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GM12878 motif sites were then filtered to include only those for which P(K562) ≥ 0.4. These 
filtered motif sites were then used to train an RBF kernel SVM using 5-fold cross validation. Sample 
weights were included for the SVM training such that training samples more similar to the K562 
test samples would receive a greater weight. I defined the weight to be P(K562)/P(GM12878). 
Table 2.5 provides the results of applying data set shift correction to DeFCoM for 17 transcription 
factors.  
Sequencing Depth Matching 
Another consideration related to cross cell-line analyses is the difference in sequencing 
depth between the training and testing set affecting DeFCoM performance. When the training data 
set comes from DNase-seq/ATAC-seq data with a lower sequencing depth than the test data, the 
dynamic range of DNaseI digestion frequencies at motif sites has the potential to be greater in the 
test set. Arguably, this could create another scenario where data set shift is a concern. Although I 
incorporate a square root transformation of the DNaseI digestion frequencies into the DeFCoM 
framework to mitigate dynamic range issues, I also tested if matching the sequencing depths 
between the training and testing data would improve DeFCoM’s classification accuracy. 
Using the subsampling feature in SAMTools (Li et al., 2009), I down-sampled the K562 
DNase-seq data to match the GM12878 DNase-seq data sequencing depth. I then used the GM12878 
and K562 data to generate the training and test set feature vectors respectively. With the GM12878 
feature vectors I used 5-fold cross validation to train the RBF kernel SVM of DeFCoM, and I applied 
the trained model to the feature vector representations of the down-sampled K562 samples. Table 
2.5 provides the results of this evaluation for 17 transcription factors. Compared to the model 
selection procedure, both the data set shift correction and down-sampling approaches produced 
worse classification performance.  
 
 
26 
 
Multiple variables impact motif-centric footprinting 
In addition to addressing the heterogeneity of DNaseI signal at motif sites, my analyses 
provide insights into some variables that may affect motif-centered footprinting performance, 
though this is certainly not an exhaustive list of contributing factors. My observations suggest that 
the “footprintability” i.e., the quality of footprinting, of any particular data set is a function of 
several characteristics. I noted that features of the data from a particular cell-line and the specific 
TF being considered can contribute to footprintability. For instance, the pAUC is 0.36 higher on 
average in K562 compared to HepG2 for all cross validation experiments (Figure 2.9), suggesting 
that footprint signals in K562 are better overall. Within GM12878, the cross validation pAUC scores 
across TFs range from 0.210 to 0.915, highlighting the variability in footprintability across TFs. 
Lastly, pAUCs for CHD2 are higher than CEBPB in all cell types (Figure 2.11), suggesting active 
footprints for some factors are in general easier to discriminate than for others.  
It is important to note that the four cell lines I use span a wide range of sequencing depths 
(Table 2.6). I wondered how closely footprintability was associated with total sequencing depth. 
Since the signal quality across data sets can widely vary, I also wondered whether the “effective” 
sequencing depth, based on the number of reads in DNaseI hypersensitive sites, was more 
important than simply the raw sequencing depth. I used mean pAUC values from DeFCoM’s nested 
cross validation experiments for each TF across all cell lines to compare footprintability based on 
total and effective sequencing-depth. Overall, I found that for most factors, accuracy increased 
nonlinearly with respect to total sequencing depth, but not effective sequencing depth (Figure 
2.12).   
To better understand the trade-off between sequencing depth and signal quality, I focused 
on data from GM12878 and H1-hESC since they possess very different signal-to-noise ratios (0.19 
versus 0.43 FRiP score). I performed 5-fold nested cross validation using DeFCoM and data from 
each cell line subsampled to 25, 50, 75, and 100 million aligned reads and calculated pAUCs for 
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each. The effect of raw sequencing depth versus signal quality became more apparent when I 
assessed changes in pAUC at a fixed 5% FPR under this framework (Figure 2.13). As expected, the 
changes in pAUC vary by TF, but performance in the H1-hESC cell-line was less affected by 
increased sequencing depth. This suggests that for data with better signal-to-noise, informative 
DNaseI signals are present at lower sequencing depths, resulting in smaller improvements in 
footprintability with increased sequencing depth. I see the opposite in the GM12878 cell-line where 
increased sequencing depth substantially improves accuracy. When looking across sequencing 
depths at the number of H1-hESC active motif sites that are in the evaluation sets, I notice that more 
active sites meet the coverage filtering thresholds as sequencing depth increases. This shows that 
although much of the DNaseI signals may be present at lower sequencing depths, a higher 
sequencing depth can provide gains in sensitivity. The improvements in sensitivity will vary by TF, 
as evidenced by large increases for CTCF and RAD21 but significantly smaller increases for other 
TFs (Figure 2.14). 
Interestingly, active footprints for some TFs were more accurately identified in GM12878 
than H1-hESC at equivalent sequencing depths despite the reduced signal-to-noise. This may be due 
to the FRiP score serving as a global signal quality measure rather than at the level of individual 
TFs. To investigate this further, I analyzed the ratio of active motif sites to inactive sites for several 
TFs and found that many decreased drastically in GM12878 data with increasing sequencing depth 
compared to the same ratios in H1-hESC data (Figure 2.15A). For instance, in GM12878 for SP1 this 
ratio was 16.8 at a sequencing depth of 25 million reads but decreased to 0.55 at 100 million reads. 
In H1-hESC, I observed a much smaller ratio change from 0.48 to 0.10 for the same factor (Figure 
2.15B). The large changes in active to inactive site ratios in GM12878 suggest that in data with 
lower signal-to-noise, the number of inactive sites is more affected by sequencing depth, at least 
based on my criteria. Across all 18 TFs in GM12878, I witnessed a -0.71 Pearson correlation on 
average between the active to inactive site ratios and pAUCs for a TF. In H1-hESC the mean 
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correlation was -0.89. Overall, my results suggest that increasing sequencing depth to improve 
accuracy will primarily benefit noisy data sets, and that signal quality in data will affect accuracy by 
varying the number of inactive motif sites that are considered compared to the number of active 
motif sites.  
 
DeFCoM outperforms other footprinters 
To provide a comprehensive study of footprinting from a motif-centric perspective, I 
compared DeFCoM with nine competing footprinters: BinDNase, CENTIPEDE, cut density, 
DNase2TF, HINT, FOS, msCentipede, PIQ, and Wellington (Table 2.1). All methods were assessed 
based on their ability to correctly classify the same sets of motif sites for 18 TFs as active or inactive 
in the given cell-line. Partial AUCs (5% FPR) were calculated to compare the methods. For the 
supervised learning footprinters (DeFCoM and BinDNase), training was performed using data from 
K562 for test sets in GM12878, H1-hESC, and Hepg2, and in GM12878 for test sets in K562. To 
summarize performance across all data sets, I ranked each method by pAUC for each of the 71 tests 
and calculated their mean rank across all tests (Figure 2.16). DeFCoM ranked first in 25 of the 71 
evaluation sets (34.7%) and second in an additional 29 test sets (40.3%). I see even better 
performance by DeFCoM when using pAUCs from within cell-line cross validation for the two 
supervised methods. DeFCoM ranked first 39 times (54.9%) and second 23 times (32.4%) (Figure 
2.17). DeFCoM had the best mean rank for results from both the cross cell-line and cross validation 
tests followed by BinDNase and msCentipede. Interestingly, cut density, which simply predicts 
footprints based on the number of DNase-seq reads, had the 4th best mean rank despite not using 
any information about actual footprint signals (Figures 2.16B and 2.18). Previous studies witnessed 
similarly reasonable performance for this simple method [63,65], but Gusmao et al. showed that cut 
density’s accuracy relative to other footprinters suffers at a 1% FPR [66]. In my study, cut density 
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had the 5th best mean rank using pAUCs at a 1% FPR (Figure 2.19), still outperforming 5 other 
footprinters.  
The improved classification accuracy of both DeFCoM and BinDNase over the unsupervised 
approaches highlights the utility of learning a discriminative model for motif-centric footprinting. 
Because DeFCoM defaults to a linear SVM model unless more complex modeling is required, I 
expect it to perform at least as well as BinDNase, which uses another type of linear model, logistic 
regression. Also, including the nonlinear RBF kernel enables DeFCoM to outperform BinDNase by as 
much as 0.0835 pAUC, though I note that the two footprinters have essentially the same accuracy 
for 59 of the 71 data sets (pAUC difference < 0.025). This increases to 65 of the 71 data sets using 
pAUC difference < 0.05 (Figure 2.20). BinDNase includes a computationally expensive greedy 
backward search to determine optimal features. Impressively, this shows that DeFCoM can achieve 
a similar or better accuracy than BinDNase using a set of predefined features that can be computed 
more efficiently. The greater overall performance of msCentipede relative to the other 
unsupervised footprinters indicates that modeling heterogeneity with an unsupervised method can 
produce comparable results to DeFCoM in some cases, though I note that for the factor TBP in 
HepG2, a model could not be learned in reasonable time (model training terminated after 60 days). 
For 48 of the 71 test sets, DeFCoM and msCentipede perform similarly (pAUC difference < 0.05), but 
using supervised learning affords DeFCoM better performance in 16 of the data sets (pAUC > 0.05), 
including a pAUC difference of 0.25 for the RAD21 test sets.   
 
ATAC-seq is comparable to DNase-seq for footprinting 
Like DNase-seq, ATAC-seq assays for accessible chromatin and can generate visible 
footprints in aggregate accessibility profiles for active motif sites. Its low biological sample material 
requirement relative to DNase-seq makes it an appealing alternative when this is a limiting factor. I 
evaluated DeFCoM using GM12878 ATAC-seq data to determine its utility for motif-centric 
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supervised footprinting. I applied 5-fold nested cross validation with the ATAC-seq data to train and 
test DeFCoM models for 18 TFs. The pAUC at 5% FPR and full AUC were averaged across the 5 folds 
from the cross-validation. I then repeated the nested cross validation with DNase-seq data on the 
same set of active and inactive sites (Figure 2.21). Despite the differences in sequencing depth of 
the DNase-seq (245 million reads) and ATAC-seq data (93 million reads), the pAUC and full AUC 
values are generally similar, with DeFCoM performing slightly better when using DNase-seq (mean 
pAUC difference = 0.072, mean AUC difference = 0.043). Overall this supports the feasibility of 
extending DeFCoM to experiments that use ATAC-seq. 
 
DeFCoM as an open-source software package 
Poor implementation and usability hinder the adoption of otherwise practical tools in the 
scientific community. With this in mind, I implemented DeFCoM to be an easy-to-use software 
package with a code-base that follows good software design principles. For both end-users and 
developers, I make my code freely accessible via a code repository 
(https://bitbucket.org/bryancquach/defcom) with extensive API documentation and a user guide. 
DeFCoM is the only supervised learning footprinter supported by thorough documentation to 
improve ease of use. I also include well-commented scripts to handle common data processing 
tasks for footprint analysis. DeFCoM is implemented in the Python programming language within 
an object-oriented framework that enhances modularity of the code for easy debugging, 
modification, and extension. Furthermore, because DeFCoM is a data-intensive method, I make use 
of scalable programming techniques such as batch processing and parallel computing to ensure 
feasibility for use on a modern desktop machine. As an open-source software package, I encourage 
the community to modify and adapt my code for further advancements in footprinting research  
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DISCUSSION 
Our study provides novel insights into variables that affect identification of DNaseI 
footprints, and for the assessment of footprinter performance. Aggregate DNaseI digestion profiles 
do not represent well the footprint patterns seen at individual sites, thus footprinters that use 
models based on aggregate or general footprint signal patterns may suffer. Inactive motif sites for 
one TF may be bound by a TF that creates a footprint and thus be misclassified, at least for the 
original TF. This is a general challenge in the assessment of motif-centric approaches, but this does 
not necessarily reflect a weakness in these footprinters. The motif-centric footprinter is correctly 
identifying a footprint, though it mistakenly attributes it to the wrong factor. Arguably, this is better 
than spuriously identifying a footprint at a location where no factor is bound. This serves as an 
important consideration for both interpreting footprint predictions and assessing footprinters in a 
motif-based framework. 
Heterogeneity in DNaseI digestion signals at motif sites exists, and I show that my DeFCoM 
footprinter benefits from being aware of this heterogeneity. At the same time, I also show that 
incorporating the flexibility to use more or less complicated models depending on the particular TF, 
cell line, and data set is important as well. DNase-seq and ATAC-seq footprint signals will vary 
based on biological and technical factors that influence the data. Footprinters that can model 
footprints well across this range of variability will obviously be more robust. Supporting this, 
msCentipede also models heterogeneity and was the best performing method that did not use 
supervised learning, though I found this method may be limited by unreasonable training times for 
specific data sets. 
We show that determining appropriate sequencing depth for footprinting is not easy and is 
affected by many variables. I observed sequencing depth affected footprinter accuracy less when 
the DNase-seq data had a better signal-to-noise ratio, but I also witnessed variation in TF-specific 
footprintability at equivalent sequencing depths between cell-lines. Sung et al. provided evidence 
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that DNA residence time plays a role in the clarity of a footprint signal [53]. Likewise, greater 
sequencing depth generally increased the number of sites where footprints were identified, but the 
benefit to individual factors varies. Biological variables such as these need to be further assessed on 
a per-TF basis in conjunction with technical factors to better realize which of these most strongly 
contribute to footprintability. This knowledge would help determine how to appropriately design 
footprinting experiments.  
For footprinters such as DeFCoM that use supervised learning, the concordance between 
features of the training and test sets become important. Although this introduces added complexity, 
it can be leveraged to achieve more targeted results. For instance, high-confidence footprints in 
DNaseI hypersensitive sites could be identified by tailoring the training set to include only sites in 
areas of high DNaseI activity. Doing so would make the model more representative of these 
stronger footprint signals, though at the expense of generalizability to low signal regions. Potential 
variability between training and test sets should be minimal for situations in which data is 
generated from the same cell type for both but possibly under different experimental conditions.  
A comprehensive evaluation of footprinting was reported in [66]. Though more rigorous 
than previous comparative analyses, their evaluation strategy was more informative for 
understanding footprinters in a de novo footprinting context. I provide a complementary 
footprinter evaluation from a motif-centric perspective. In my work, I focused on results at a 5% 
FPR to provide more practical insight on footprint detection accuracy at acceptable error rates. The 
ability of both DeFCoM and BinDNase to consistently outperform unsupervised footprinters, with 
the possible exception of msCentipede, further supports supervised learning-based methods. I note 
that my results contradict accuracy levels found in the previous evaluation for several footprinters. 
This demonstrates that evaluation methods can largely influence reported performance. The de 
novo footprinters DNase2TF and FOS performed poorly in my tests, because they failed to report a 
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score for many of the motif sites in the test set. My results in conjunction with previous studies 
highlight the importance of evaluating a footprinter in the context for which it was designed.  
ATAC-seq is quickly being adopted as it requires less biological starting material, and I show 
DeFCoM performs comparably with these data. As I learn more about the nuances of footprinting in 
both DNase- and ATAC-seq, I expect footprinters will adapt accordingly. In light of this, my 
implementation of DeFCoM in an open-source, modularized and object-oriented framework makes 
it conducive to modification and improvement. As such, I welcome and encourage collaborative 
efforts with others in the scientific community to address the needs of researchers as the field 
evolves. 
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Figure 2.1.   Motif logos for NRF1, CHD2, and CEBPB.  Sequence logo representations of position 
weight matrices used to evaluate DNaseI signal profile heterogeneity. 
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Figure 2.2 Within and between class variability in DNaseI digestion signal at motif sites. A) 
Per base means (µ) and standard deviations (σ) of DNaseI signal aggregated for NRF1 motif sites 
active (+) and inactive (-) in K562. B) K562 DNase-seq and ChIP-seq signal at an NRF1 motif site 
(Chr1:16,175,923-16,176,022) from the active class and C) two neighboring NRF1 inactive sites 
(Chr22:38,966,291-38,966,390). D) Pairwise Pearson correlations between the top 2000 NRF1 
motif sites from the active and inactive class ranked by DNaseI digestion signal. 
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Figure 2.3.   K562 DNaseI signal profiles. K562 aggregate mean (µ) and standard deviation (σ) 
DNaseI digestion profiles for the active (+) and inactive (-) motif site classes of 17 transcription 
factors.
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Figure 2.4.   Coefficients of variation for K562 DNaseI digestion profiles. Coefficients of 
variation derived from K562 DNaseI digestion profiles for the active (+) and inactive (-) motif site 
classes of 17 transcription factors. The dashed horizontal gray line denotes a coefficient of variation 
of 1. Values above this signify that the standard deviation exceeds the mean
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Figure 2.5.   Correlations between aggregate and individual DNaseI  digestion profiles. 
Histograms conveying the spread in Pearson correlation coefficients i) between K562 DNaseI signal 
at active motif sites and the active class aggregate mean DNaseI cut profile for A) CEBPB, B) CHD2, 
and C) NRF1. ii) between K562 DNaseI signal at active motif sites and the inactive class aggregate 
mean DNaseI cut profile for D) CEBPB, E) CHD2, and F) NRF1. iii) between K562 DNaseI signal at 
inactive motif sites and the inactive class aggregate mean DNaseI cut profile for G) CEBPB, H) CHD2, 
and I) NRF1. iv) between K562 DNaseI signal at inactive motif sites and the active class aggregate 
mean DNaseI cut profile for J) CEBPB, K) CHD2, and L) NRF1. 
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Figure 2.6.   Pairwise correlation heatmaps for individual DNaseI  digestion profiles. 
Correlations between individual DNaseI digestion profiles at A) CEBPB and B) CHD2 motif sites in 
K562. After filtering active and inactive NRF1 motif site sets for the top 2000 sites ranked by total 
DNaseI digestion events (for CHD2 the inactive set had less than 2000 sites), we applied 
hierarchical clustering to the DNaseI signal profiles based on pairwise Pearson correlations and 
visualized the correlation values as heatmaps.  
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Figure 2.7.   Motif site overlap with ChIP-seq peaks. A) The fraction of K562 active motif sites for 
a transcription factor that overlap a ChIP-seq peak for another factor (100 transcription factors 
were included). B) The same analysis as in (A) but using a 50 bp window centered on the ChIP-seq 
peak offset instead of the full peak region. C) The fraction of K562 inactive motif sites for a 
transcription factor that overlap a ChIP-seq peak for another factor. D) The same analysis as in (C) 
but using a 50 bp window centered on the ChIP-seq peak offset instead of the full peak region. 
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Figure 2.8.   Overview of the DeFCoM classification framework. In the training phase, active and 
inactive motif site sets are constructed using ChIP-seq data. Corresponding DNase-seq data is used 
to produce DNaseI digestion profiles for each motif site. These profiles are converted into feature 
vectors that go into model selection and SVM training. The trained SVM model can then be used to 
classify motif sites as active or inactive in a different experiment or condition for which DNase-seq 
data are available, without the need ChIP-seq data. 
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Figure 2.9.   Comparison of DeFCoM model variants. A) Partial (5% FPR) and full AUCs from 
evaluations of DeFCoM-RBF for 18 TFs in 4 cell-lines. Black horizontal lines signify values if 
classifications were random. B) Comparison of DeFCoM to DeFCoM-linear by differences in pAUCs 
for the same test sets as A. 
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Figure 2.10.   DeFCoM training phase model selection performance. Assessment of when the 
model selection procedure chooses the better SVM type (linear vs. RBF kernel) during the training 
phase of cross cell-line tests for 18 TFs. Optimal and suboptimal denote whether the model 
selection procedure chose the SVM type that produced the higher pAUC (FPR 5%) values. 
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Figure 2.11.   Classification performance of DeFCoM-linear vs. DeFCoM-RBF. Distribution of 
pAUC (5% FPR) scores by transcription factor from cross cell-line tests for A) DeFCoM-linear and 
B) DeFCoM-RBF. C) Comparison of DeFCoM to DeFCoM-linear by pAUC difference (5% FPR) for 18 
TFs in cross validation and cross cell-line evaluations. 
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Figure 2.12.   Comparisons of DeFCoM classification performance with effective and total 
sequencing depth. Comparison of DeFCoM classification performance at A) effective sequencing 
depths for the four cell-lines used and B) total sequencing depths for the same cell-lines. Notably, 
pAUC values vary widely across TFs and poorly correlate with sequencing depth for most 
transcription factors. 
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Figure 2.13.   DeFCoM classification performance on subsampled data. Comparison of DeFCoM 
classification performance with A) subsampled GM12878 and B) H1-hESC DNase-seq data. H1-hESC 
possesses a higher signal-to-noise ratio and is affected less by increased sequencing depth. C) The 
pAUC difference between GM12878 and H1-hESC for each TF at the four subsampled sequencing 
depths 
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Figure 2.14.   Active motif site set size at various sequencing depths. Number of motif sites that 
meet filtering criteria in the active set across sequencing depths in H1-hESC. 
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Figure 2.15.   Active to inactive motif site set size ratio at various sequencing depths. 
Comparison of the ratio of active (+) motif sites to inactive (-) motif sites across four subsampled 
sequencing depths in A) GM12878 and B) H1-hESC DNase-seq data. C) The difference in ratios 
between GM12878 and H1-hESC for each TF at the four subsampled sequencing depths. 
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Figure 2.16.   Performance ranking of footprinters. A) Frequency at which each footprinter 
obtains a particular rank (based on 5% FPR pAUC) for all 71 evaluation sets. B) Mean rank, derived 
from A, of each footprinter. 
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Figure 2.17.   Performance ranking of footprinters using cross validation results. Comparison 
of footprinters when DeFCoM and BinDNase mean pAUCs from cross-validation are used. A) 
Frequency at which each footprinter obtains a rank (based on 5% FPR pAUC) for all 71 evaluation 
sets. B) Mean rank, derived from A, of each footprinter 
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Figure 2.18.   Partial AUC comparison between DeFCoM and Cut Density. Comparison between 
DeFCoM and Cut Density pAUCs (5% FPR) for 71 test sets from 18 transcription factors and 4 cell-
lines. Gray, horizontal dashed lines are at the -0.05 and 0.05 pAUC difference. 
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Figure 2.19.   Performance ranking of footprinters at a 1% FPR cutoff for pAUCs. Comparison 
of footprinters by mean rank of 71 test sets. Mean ranks are based on pAUCs at a 1% FPR. 
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Figure 2.20.   Partial AUC comparison between DeFCoM and BinDNase. Comparison between 
DeFCoM and BinDNase pAUCs (5% FPR) for 71 test sets from 18 transcription factors and 4 cell-
lines. Gray, horizontal dashed lines are at the -0.05, -0.025, 0.025 and 0.05 pAUC differences. 
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Figure 2.21. Comparison between using DNase-seq and ATAC-seq with DeFCoM. Comparison 
between using GM12878 ATAC-seq and DNase-seq data with DeFCoM. Partial AUC (left) and full 
AUC (right) results from cross-validation tests for 18 TFs 
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Footprinter 
Name 
Author Footprinter 
Type 
Classification 
Algorithm 
Included in 
Comparison 
Boyle et al. [38] Motif-centric Probabilistic Graphical 
Model (Hidden Markov 
Model) 
No 
DBFP [45] De novo Probabilistic Graphical 
Model (Dynamic 
Bayesian Network) 
No 
DeFCoM - Motif-centric Support Vector 
Machine* 
Yes 
BinDNase [46] Motif-centric Logistic Regression* Yes 
CENTIPEDE [50] Motif-centric Bayesian hierarchical 
mixture model 
Yes 
Cut Density - Motif-centric Window-based 
summary statistic 
Yes 
DNase2TF [53] De novo Window-based 
summary statistic 
Yes 
FLR [67] Motif-centric Mixture model No 
FOS [48] De novo Window-based 
summary statistic 
Yes 
HINT [68] De novo Probabilistic Graphical 
Model (Hidden Markov 
Model) 
Yes 
Millipede [47] Motif-centric Logistic Regression No 
msCentipede [51] Motif-centric Bayesian multi-scale 
model 
Yes 
PIQ [52] Motif-centric Gaussian process and 
expectation 
propagation 
Yes 
Wellington [49] De novo Binomial test Yes 
*=Supervised learning method 
Table 2.1.   Summary of footprinters. Names of existing footprint detection methods and 
characteristics of their approach. The last column indicates if they were included in the method 
classification performance comparison. 
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Cell-line Files 
GM12878 wgEncodeOpenChromDnaseGm12878AlnRep1.bam 
wgEncodeOpenChromDnaseGm12878AlnRep2.bam 
wgEncodeOpenChromDnaseGm12878AlnRep3.bam 
wgEncodeOpenChromDnaseGm12878AlnRep4.bam 
wgEncodeOpenChromDnaseGm12878AlnRep5.bam 
H1-hESC wgEncodeOpenChromDnaseH1hescAlnRep1.bam 
wgEncodeOpenChromDnaseH1hescAlnRep2.bam 
HepG2 wgEncodeOpenChromDnaseHepg2AlnRep1.bam 
wgEncodeOpenChromDnaseHepg2AlnRep2.bam 
wgEncodeOpenChromDnaseHepg2AlnRep3.bam 
K562 wgEncodeOpenChromDnaseK562AlnRep1V2.bam 
wgEncodeOpenChromDnaseK562AlnRep2V2.bam 
wgEncodeOpenChromDnaseK562AlnRep3V2.bam 
 
Table 2.2   ENCODE DNase-seq data files. File names for DNase-seq data used. Obtained from 
http://hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncodeOpenChromDnase/. 
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Transcription Factor Files* 
CEBPB wgEncodeAwgTfbsHaibGm12878Cebpbsc150V0422111UniPk.narrowPeak.gz 
wgEncodeAwgTfbsHaibHepg2Cebpbsc150V0416101UniPk.narrowPeak.gz 
wgEncodeAwgTfbsHaibK562Cebpbsc150V0422111UniPk.narrowPeak.gz 
wgEncodeAwgTfbsSydhH1hescCebpbIggrabUniPk.narrowPeak.gz 
wgEncodeHaibTfbsGm12878Cebpbsc150V0422111AlnRep1.bam 
wgEncodeHaibTfbsGm12878Cebpbsc150V0422111AlnRep2.bam 
wgEncodeHaibTfbsHepg2Cebpbsc150V0416101AlnRep1.bam 
wgEncodeHaibTfbsHepg2Cebpbsc150V0416101AlnRep2.bam 
wgEncodeHaibTfbsK562Cebpbsc150V0422111AlnRep1.bam 
wgEncodeHaibTfbsK562Cebpbsc150V0422111AlnRep2.bam 
wgEncodeSydhTfbsH1hescCebpbIggrabAlnRep1.bam 
wgEncodeSydhTfbsH1hescCebpbIggrabAlnRep2.bam 
CHD2 wgEncodeAwgTfbsSydhGm12878Chd2ab68301IggmusUniPk.narrowPeak.gz 
wgEncodeAwgTfbsSydhH1hescChd2IggrabUniPk.narrowPeak.gz 
wgEncodeAwgTfbsSydhHepg2Chd2ab68301IggrabUniPk.narrowPeak.gz 
wgEncodeAwgTfbsSydhK562Chd2ab68301IggrabUniPk.narrowPeak.gz 
wgEncodeSydhTfbsGm12878Chd2ab68301IggmusAlnRep1.bam 
wgEncodeSydhTfbsGm12878Chd2ab68301IggmusAlnRep2.bam 
wgEncodeSydhTfbsH1hescChd2IggrabAlnRep1.bam 
wgEncodeSydhTfbsH1hescChd2IggrabAlnRep2.bam 
wgEncodeSydhTfbsHepg2Chd2ab68301IggrabAlnRep1.bam 
wgEncodeSydhTfbsHepg2Chd2ab68301IggrabAlnRep2.bam 
wgEncodeSydhTfbsK562Chd2ab68301IggrabAlnRep1.bam 
wgEncodeSydhTfbsK562Chd2ab68301IggrabAlnRep2.bam 
CTCF wgEncodeAwgTfbsBroadGm12878CtcfUniPk.narrowPeak.gz 
wgEncodeAwgTfbsBroadH1hescCtcfUniPk.narrowPeak.gz 
wgEncodeAwgTfbsBroadHepg2CtcfUniPk.narrowPeak.gz 
wgEncodeAwgTfbsBroadK562CtcfUniPk.narrowPeak.gz 
wgEncodeHaibTfbsH1hescCtcfsc5916V0416102AlnRep1.bam 
wgEncodeHaibTfbsH1hescCtcfsc5916V0416102AlnRep2.bam 
wgEncodeHaibTfbsHepg2Ctcfsc5916V0416101AlnRep1.bam 
wgEncodeHaibTfbsHepg2Ctcfsc5916V0416101AlnRep2.bam 
wgEncodeHaibTfbsK562CtcfcPcr1xAlnRep1V2.bam 
wgEncodeHaibTfbsK562CtcfcPcr1xAlnRep2V2.bam 
wgEncodeSydhTfbsGm12878Ctcfsc15914c20StdAlnRep1.bam 
wgEncodeSydhTfbsGm12878Ctcfsc15914c20StdAlnRep2.bam 
EP300 wgEncodeAwgTfbsBroadK562P300UniPk.narrowPeak.gz 
wgEncodeAwgTfbsHaibGm12878P300Pcr1xUniPk.narrowPeak.gz 
wgEncodeAwgTfbsHaibH1hescP300V0416102UniPk.narrowPeak.gz 
wgEncodeAwgTfbsHaibHepg2P300V0416101UniPk.narrowPeak.gz 
wgEncodeHaibTfbsGm12878P300Pcr1xAlnRep1.bam 
wgEncodeHaibTfbsGm12878P300Pcr1xAlnRep2.bam 
wgEncodeHaibTfbsH1hescP300V0416102AlnRep1.bam 
wgEncodeHaibTfbsH1hescP300V0416102AlnRep2.bam 
wgEncodeHaibTfbsHepg2P300V0416101AlnRep1.bam 
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wgEncodeHaibTfbsHepg2P300V0416101AlnRep2.bam 
wgEncodeSydhTfbsK562P300IggrabAlnRep1.bam 
wgEncodeSydhTfbsK562P300IggrabAlnRep2.bam 
GABPA wgEncodeAwgTfbsHaibGm12878GabpPcr2xUniPk.narrowPeak.gz 
wgEncodeAwgTfbsHaibH1hescGabpPcr1xUniPk.narrowPeak.gz 
wgEncodeAwgTfbsHaibHepg2GabpPcr2xUniPk.narrowPeak.gz 
wgEncodeAwgTfbsHaibK562GabpV0416101UniPk.narrowPeak.gz 
wgEncodeHaibTfbsGm12878GabpPcr2xAlnRep1.bam 
wgEncodeHaibTfbsGm12878GabpPcr2xAlnRep2.bam 
wgEncodeHaibTfbsH1hescGabpPcr1xAlnRep1.bam 
wgEncodeHaibTfbsH1hescGabpPcr1xAlnRep2.bam 
wgEncodeHaibTfbsHepg2GabpPcr2xAlnRep1.bam 
wgEncodeHaibTfbsHepg2GabpPcr2xAlnRep2.bam 
wgEncodeHaibTfbsK562GabpV0416101AlnRep1.bam 
wgEncodeHaibTfbsK562GabpV0416101AlnRep2.bam 
JUN-D wgEncodeAwgTfbsHaibH1hescJundV0416102UniPk.narrowPeak.gz 
wgEncodeAwgTfbsHaibHepg2JundPcr1xUniPk.narrowPeak.gz 
wgEncodeAwgTfbsSydhGm12878JundUniPk.narrowPeak.gz 
wgEncodeAwgTfbsSydhK562JundIggrabUniPk.narrowPeak.gz 
wgEncodeHaibTfbsH1hescJundV0416102AlnRep1.bam 
wgEncodeHaibTfbsH1hescJundV0416102AlnRep2.bam 
wgEncodeHaibTfbsHepg2JundPcr1xAlnRep1.bam 
wgEncodeHaibTfbsHepg2JundPcr1xAlnRep2.bam 
wgEncodeSydhTfbsGm12878JundIggrabAlnRep1.bam 
wgEncodeSydhTfbsK562JundIggrabAlnRep2.bam 
MAFK wgEncodeAwgTfbsSydhH1hescMafkIggrabUniPk.narrowPeak.gz 
wgEncodeAwgTfbsSydhHepg2Mafkab50322IggrabUniPk.narrowPeak.gz 
wgEncodeAwgTfbsSydhK562Mafkab50322IggrabUniPk.narrowPeak.gz 
wgEncodeSydhTfbsGm12878MafkIggmusPk.narrowPeak.gz 
wgEncodeSydhTfbsGm12878MafkIggmusAlnRep1.bam 
wgEncodeSydhTfbsGm12878MafkIggmusAlnRep2.bam 
wgEncodeSydhTfbsH1hescMafkIggrabAlnRep1.bam 
wgEncodeSydhTfbsH1hescMafkIggrabAlnRep2.bam 
wgEncodeSydhTfbsHepg2Mafkab50322IggrabAlnRep1.bam 
wgEncodeSydhTfbsHepg2Mafkab50322IggrabAlnRep2.bam 
wgEncodeSydhTfbsK562Mafkab50322IggrabAlnRep1.bam 
wgEncodeSydhTfbsK562Mafkab50322IggrabAlnRep2.bam 
MAX wgEncodeAwgTfbsHaibK562MaxV0416102UniPk.narrowPeak.gz 
wgEncodeAwgTfbsSydhGm12878MaxIggmusUniPk.narrowPeak.gz 
wgEncodeAwgTfbsSydhH1hescMaxUcdUniPk.narrowPeak.gz 
wgEncodeAwgTfbsSydhHepg2MaxIggrabUniPk.narrowPeak.gz 
 
wgEncodeHaibTfbsK562MaxV0416102AlnRep1.bam 
wgEncodeHaibTfbsK562MaxV0416102AlnRep2.bam 
wgEncodeSydhTfbsGm12878MaxIggmusAlnRep1.bam 
wgEncodeSydhTfbsGm12878MaxIggmusAlnRep2.bam 
wgEncodeSydhTfbsH1hescMaxUcdAlnRep1V2.bam 
wgEncodeSydhTfbsH1hescMaxUcdAlnRep2V2.bam 
wgEncodeSydhTfbsHepg2MaxIggrabAlnRep1.bam 
wgEncodeSydhTfbsHepg2MaxIggrabAlnRep2.bam 
MYC wgEncodeAwgTfbsSydhH1hescCmycIggrabUniPk.narrowPeak.gz 
wgEncodeAwgTfbsSydhK562CmycUniPk.narrowPeak.gz 
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wgEncodeAwgTfbsUtaGm12878CmycUniPk.narrowPeak.gz 
wgEncodeAwgTfbsUtaHepg2CmycUniPk.narrowPeak.gz 
wgEncodeOpenChromChipGm12878CmycAlnRep1.bam 
wgEncodeOpenChromChipGm12878CmycAlnRep2.bam 
wgEncodeOpenChromChipHepg2CmycAlnRep1.bam 
wgEncodeOpenChromChipHepg2CmycAlnRep2.bam 
wgEncodeOpenChromChipHepg2CmycAlnRep3.bam 
wgEncodeSydhTfbsH1hescCmycIggrabAlnRep1.bam 
wgEncodeSydhTfbsH1hescCmycIggrabAlnRep2.bam 
wgEncodeSydhTfbsK562CmycIggrabAlnRep1.bam 
wgEncodeSydhTfbsK562CmycIggrabAlnRep2.bam 
NRF1 wgEncodeAwgTfbsSydhGm12878Nrf1IggmusUniPk.narrowPeak.gz 
wgEncodeAwgTfbsSydhH1hescNrf1IggrabUniPk.narrowPeak.gz 
wgEncodeAwgTfbsSydhHepg2Nrf1IggrabUniPk.narrowPeak.gz 
wgEncodeAwgTfbsSydhK562Nrf1IggrabUniPk.narrowPeak.gz 
wgEncodeSydhTfbsGm12878Nrf1IggmusAlnRep1.bam 
wgEncodeSydhTfbsGm12878Nrf1IggmusAlnRep2.bam 
wgEncodeSydhTfbsH1hescNrf1IggrabAlnRep1.bam 
wgEncodeSydhTfbsH1hescNrf1IggrabAlnRep2.bam 
wgEncodeSydhTfbsHepg2Nrf1IggrabAlnRep1.bam 
wgEncodeSydhTfbsHepg2Nrf1IggrabAlnRep2.bam 
wgEncodeSydhTfbsK562Nrf1IggrabAlnRep1.bam 
wgEncodeSydhTfbsK562Nrf1IggrabAlnRep2.bam 
RAD21 wgEncodeAwgTfbsHaibGm12878Rad21V0416101UniPk.narrowPeak.gz 
wgEncodeAwgTfbsHaibH1hescRad21V0416102UniPk.narrowPeak.gz 
wgEncodeAwgTfbsHaibHepg2Rad21V0416101UniPk.narrowPeak.gz 
wgEncodeAwgTfbsHaibK562Rad21V0416102UniPk.narrowPeak.gz 
wgEncodeHaibTfbsGm12878Rad21V0416101AlnRep1.bam 
wgEncodeHaibTfbsGm12878Rad21V0416101AlnRep2.bam 
wgEncodeHaibTfbsH1hescRad21V0416102AlnRep1.bam 
wgEncodeHaibTfbsH1hescRad21V0416102AlnRep2.bam 
wgEncodeHaibTfbsHepg2Rad21V0416101AlnRep1.bam 
wgEncodeHaibTfbsHepg2Rad21V0416101AlnRep2.bam 
wgEncodeHaibTfbsK562Rad21V0416102AlnRep1.bam 
wgEncodeHaibTfbsK562Rad21V0416102AlnRep2.bam 
REST wgEncodeAwgTfbsHaibGm12878NrsfPcr1xUniPk.narrowPeak.gz 
wgEncodeAwgTfbsHaibH1hescNrsfV0416102UniPk.narrowPeak.gz 
wgEncodeAwgTfbsHaibHepg2NrsfV0416101UniPk.narrowPeak.gz 
wgEncodeAwgTfbsHaibK562NrsfV0416102UniPk.narrowPeak.gz 
wgEncodeHaibTfbsGm12878NrsfPcr1xAlnRep1.bam 
wgEncodeHaibTfbsGm12878NrsfPcr1xAlnRep2.bam 
wgEncodeHaibTfbsH1hescNrsfV0416102AlnRep1.bam 
wgEncodeHaibTfbsH1hescNrsfV0416102AlnRep2.bam 
wgEncodeHaibTfbsHepg2NrsfV0416101AlnRep1.bam 
wgEncodeHaibTfbsHepg2NrsfV0416101AlnRep2.bam 
wgEncodeHaibTfbsK562NrsfV0416102AlnRep1.bam 
wgEncodeHaibTfbsK562NrsfV0416102AlnRep2.bam 
RFX5 wgEncodeAwgTfbsSydhGm12878Rfx5200401194IggmusUniPk.narrowPeak.gz 
wgEncodeAwgTfbsSydhH1hescRfx5200401194IggrabUniPk.narrowPeak.gz 
wgEncodeAwgTfbsSydhHepg2Rfx5200401194IggrabUniPk.narrowPeak.gz 
wgEncodeAwgTfbsSydhK562Rfx5IggrabUniPk.narrowPeak.gz 
wgEncodeSydhTfbsGm12878Rfx5200401194IggmusAlnRep1.bam 
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wgEncodeSydhTfbsGm12878Rfx5200401194IggmusAlnRep2.bam 
wgEncodeSydhTfbsH1hescRfx5200401194IggrabAlnRep1.bam 
wgEncodeSydhTfbsH1hescRfx5200401194IggrabAlnRep2.bam 
wgEncodeSydhTfbsHepg2Rfx5200401194IggrabAlnRep1.bam 
wgEncodeSydhTfbsHepg2Rfx5200401194IggrabAlnRep2.bam 
wgEncodeSydhTfbsK562Rfx5IggrabAlnRep1.bam 
wgEncodeSydhTfbsK562Rfx5IggrabAlnRep2.bam 
SRF wgEncodeAwgTfbsHaibGm12878SrfPcr2xUniPk.narrowPeak.gz 
wgEncodeAwgTfbsHaibH1hescSrfPcr1xUniPk.narrowPeak.gz 
wgEncodeAwgTfbsHaibHepg2SrfV0416101UniPk.narrowPeak.gz 
wgEncodeAwgTfbsHaibK562SrfV0416101UniPk.narrowPeak.gz 
wgEncodeHaibTfbsGm12878SrfPcr2xAlnRep1.bam 
wgEncodeHaibTfbsGm12878SrfPcr2xAlnRep2.bam 
wgEncodeHaibTfbsH1hescSrfPcr1xAlnRep1.bam 
wgEncodeHaibTfbsH1hescSrfPcr1xAlnRep2.bam 
wgEncodeHaibTfbsHepg2SrfV0416101AlnRep1.bam 
wgEncodeHaibTfbsHepg2SrfV0416101AlnRep2.bam 
wgEncodeHaibTfbsK562SrfV0416101AlnRep1.bam 
wgEncodeHaibTfbsK562SrfV0416101AlnRep2.bam 
SP1 wgEncodeAwgTfbsHaibGm12878Sp1Pcr1xUniPk.narrowPeak.gz 
wgEncodeAwgTfbsHaibH1hescSp1Pcr1xUniPk.narrowPeak.gz 
wgEncodeAwgTfbsHaibHepg2Sp1Pcr1xUniPk.narrowPeak.gz 
wgEncodeHaibTfbsGm12878Sp1Pcr1xAlnRep1.bam 
wgEncodeHaibTfbsGm12878Sp1Pcr1xAlnRep2.bam 
wgEncodeHaibTfbsH1hescSp1Pcr1xAlnRep1.bam 
wgEncodeHaibTfbsH1hescSp1Pcr1xAlnRep2.bam 
wgEncodeHaibTfbsHepg2Sp1Pcr1xAlnRep1.bam 
wgEncodeHaibTfbsHepg2Sp1Pcr1xAlnRep2.bam 
TAF1 wgEncodeAwgTfbsHaibGm12878Taf1Pcr1xUniPk.narrowPeak.gz 
wgEncodeAwgTfbsHaibH1hescTaf1V0416102UniPk.narrowPeak.gz 
wgEncodeAwgTfbsHaibHepg2Taf1Pcr2xUniPk.narrowPeak.gz 
wgEncodeAwgTfbsHaibK562Taf1V0416101UniPk.narrowPeak.gz 
wgEncodeHaibTfbsGm12878Taf1Pcr1xAlnRep1.bam 
wgEncodeHaibTfbsGm12878Taf1Pcr1xAlnRep2.bam 
wgEncodeHaibTfbsH1hescTaf1V0416102AlnRep1.bam 
wgEncodeHaibTfbsH1hescTaf1V0416102AlnRep2.bam 
wgEncodeHaibTfbsHepg2Taf1Pcr2xAlnRep1.bam 
wgEncodeHaibTfbsHepg2Taf1Pcr2xAlnRep2.bam 
wgEncodeHaibTfbsK562Taf1V0416101AlnRep1.bam 
wgEncodeHaibTfbsK562Taf1V0416101AlnRep2.bam 
TBP wgEncodeAwgTfbsSydhGm12878TbpIggmusUniPk.narrowPeak.gz 
wgEncodeAwgTfbsSydhH1hescTbpIggrabUniPk.narrowPeak.gz 
wgEncodeAwgTfbsSydhHepg2TbpIggrabUniPk.narrowPeak.gz 
wgEncodeAwgTfbsSydhK562TbpIggmusUniPk.narrowPeak.gz 
wgEncodeSydhTfbsGm12878TbpIggmusAlnRep1.bam 
wgEncodeSydhTfbsGm12878TbpIggmusAlnRep2.bam 
wgEncodeSydhTfbsH1hescTbpIggrabAlnRep1.bam 
wgEncodeSydhTfbsH1hescTbpIggrabAlnRep2.bam 
wgEncodeSydhTfbsHepg2TbpIggrabAlnRep1.bam 
wgEncodeSydhTfbsHepg2TbpIggrabAlnRep2.bam 
wgEncodeSydhTfbsK562TbpIggmusAlnRep1.bam 
wgEncodeSydhTfbsK562TbpIggmusAlnRep2.bam 
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USF2 wgEncodeAwgTfbsSydhGm12878Usf2IggmusUniPk.narrowPeak.gz 
wgEncodeAwgTfbsSydhH1hescUsf2IggrabUniPk.narrowPeak.gz 
wgEncodeAwgTfbsSydhHepg2Usf2IggrabUniPk.narrowPeak.gz 
wgEncodeAwgTfbsSydhK562Usf2IggrabUniPk.narrowPeak.gz 
wgEncodeSydhTfbsGm12878Usf2IggmusAlnRep1.bam 
wgEncodeSydhTfbsGm12878Usf2IggmusAlnRep2.bam 
wgEncodeSydhTfbsH1hescUsf2IggrabAlnRep1.bam 
wgEncodeSydhTfbsH1hescUsf2IggrabAlnRep2.bam 
wgEncodeSydhTfbsHepg2Usf2IggrabAlnRep1.bam 
wgEncodeSydhTfbsHepg2Usf2IggrabAlnRep2.bam 
wgEncodeSydhTfbsK562Usf2IggrabAlnRep1.bam 
wgEncodeSydhTfbsK562Usf2IggrabAlnRep2.bam 
*File prefixes denote the following base URLs:  
wgEncodeAwg = http://hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncodeAwgTfbsUniform/ 
wgEncodeHaib = http://hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncodeHaibTfbs/ 
wgEncodeSydh = http://hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncodeSydhTfbs/ 
wgEncodeUchicago = http://hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncodeUchicagoTfbs/ 
wgEncodeOpenChrom = http://hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncodeOpenChromChip/ 
wgEncodeUw = http://hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncodeUwTfbs/ 
Table 2.3.   ENCODE ChIP-seq data files. File names for ChIP-seq data used in model training and 
comparisons of footprinters. 
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Transcription 
Factor 
GM12878 
Active 
GM12878 
Inactive 
H1-
hESC 
Active 
H1-
hESC 
Inactive 
HepG2 
Active 
HepG2 
Inactive 
K562 
Active 
K562 
Inactive 
CEBPB 1695 96482 2732 10517 5612 4027 11438 229030 
CHD2 7096 25202 3885 15856 3335 1599 4884 44050 
CTCF 40146 661473 40910 83590 32083 113093 49546 875895 
EP300 3481 125945 5655 95419 11998 55446 1319 663038 
GABPA 5892 177426 4427 9436 8662 119616 10456 191479 
JUND 1605 68708 2327 9776 6908 2475 20622 236287 
MAFK 592 74172 2134 19569 3127 4780 11309 224351 
MAX 10282 109679 7167 167547 9621 6646 35351 272022 
MYC 3276 84147 3314 50435 3131 7310 3875 220364 
NRF1 5293 57488 4216 51703 1821 61654 3863 151948 
RAD21 32581 668688 40368 180678 32535 46745 31817 987156 
REST 5029 332257 5282 289916 9065 84687 11713 1182481 
RFX5 2583 48576 797 15346 2646 2213 1103 237826 
SP1 11923 162337 10009 102770 11448 88642 - - 
SRF 5295 197928 2139 67446 2278 33010 2983 339381 
TAF1 11143 155336 17261 57067 14577 74334 12783 417206 
TBP 7341 121048 9695 35519 6998 9172 10052 358025 
USF2 2877 7031 2293 1416 1988 544 1721 28189 
Table 2.4.   Active and inactive motif site set sizes. 
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Transcription Factor Down-sampled K562 Data  
pAUCs (5% FPR) 
Dataset Shift Correction  
pAUCs (5% FPR) 
CEBPB 0.27 0.33 
CHD2 0.56 0.84 
CTCF 0.64 0.68 
EP300 0.57 0.60 
GABPA 0.76 0.85 
JUND 0.68 0.75 
MAFK 0.62 0.55 
MAX 0.72 0.73 
MYC 0.95 0.98 
NRF1 0.47 0.77 
RAD21 0.69 0.83 
REST 0.65 0.15 
RFX5 0.63 0.64 
SRF 0.49 0.51 
TAF1 0.90 0.93 
TBP 0.66 0.89 
USF2 0.63 0.77 
 
Table 2.5.   Classification performance for DeFCoM training phase variants. Partial AUC values for 
two variants of DeFCoM assessed on 17 TFs. Models were trained on K562 data and tested on 
GM12878 data sets.  
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Cell-line FRiP Score Total Sequencing 
Depth  
(Millions of reads) 
Effective Sequencing 
Depth  
(Millions of reads) 
GM12878 0.186284 245 45 
H1-hESC 0.427376 110 47 
HepG2 0.230881 50 11 
K562 0.231837 365 84 
 
Table 2.6.   DNase-seq signal quality and sequencing depth statistics. 
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CHAPTER III 
Characterizing molecular variation in Collaborative Cross  
mice at multiple levels of 1,3-butadiene exposure 
 
OVERVIEW 
It has been well demonstrated that genetic variation plays a large role in phenotypic 
variability. Genotype can influence modifications to the gene regulatory landscape that in turn 
affect transcription, protein expression, and ultimately a phenotype. Despite this established view 
of information flow within cells, a great challenge remains in uncovering which biological processes 
and components are at work within a particular context. A major goal in toxicogenomics is to 
understand these molecular relationships in response to toxicant exposure. For this study, I 
performed a descriptive analysis of how genetic variation and toxicant exposure relate to changes 
in chromatin organization and gene expression. Using the Collaborative Cross, a genetically diverse 
panel of multi-parent recombinant inbred mouse strains, I analyzed gene expression and chromatin 
accessibility data for lung, liver, and kidney tissue from 50 Collaborative Cross strains across three 
levels of exposure to 1,3-butadiene (BD), a gas used for the production of rubber and polymers. I 
also incorporated genetic data to perform quantitative trait loci (QTL) mapping of gene expression 
(eQTL) and chromatin accessibility (cQTL). From these analyses I observed tissue-specific 
differences in variability of gene expression and accessible chromatin in response to BD with lung 
exhibiting the largest differences. Additionally, I report eQTLs and cQTLs detected for each tissue in 
each of the three BD treatment groups and find most associations to be local for both eQTLs and 
cQTLs. In lung and kidney, “hotspot” genomic regions enriched for cQTLs were found, and we 
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identified Collaborative Cross founder strain haplotypes as candidates for driving these hotspot 
associations. 
 
INTRODUCTION 
 Chemical exposure can have distinct effects within individuals across tissues and cell types 
as well as across individuals [69,70]. To understand these differences at the molecular level, 
researchers are taking advantage of high-throughput assays for measuring various aspects of gene 
regulation, metabolism, and protein expression in relation to toxicant exposure [71]. Despite the 
use of multi-omics approaches for toxicology studies, the integration of these complementary data 
types with genotype information to gain a holistic view of toxicity susceptibility remains a 
challenge. 
 Of particular interest in this study is the DNA damage-inducing chemical 1,3-butadiene 
(BD).  At room temperature, BD is an industrial gas and is mainly used in synthetic rubber and 
polymer production.  These butadiene-based polymers are integrated into many commercial 
products such as automobiles, footwear, and plastics [72].  Additionally, BD is generally found at 
low concentrations in the environment and is also a component of tobacco smoke [73,74]. When 
inhaled, lung and liver microsomes metabolize BD into epoxide intermediates that react with DNA 
to form DNA adducts [75,76]. Importantly, mice and rat chronic inhalation studies have shown that 
BD exposure causes tumor formation in several tissues as a consequence of this DNA damage 
[77,78]. 
 At the epigenetic level, changes in bulk DNA methylation and histone modification levels in 
response to BD have been observed for mouse lung and liver tissues, but significant changes were 
not observed in kidney [69,79]. In liver, these epigenetic marks were measured across a genetically 
diverse group of 7 inbred mouse strains (NOD/ShiLtJ, CAST/EiJ, A/J, WSB/EiJ, PWK/PhJ, C57BL/6J, 
and 129S1/SvImJ), and strain-specific epigenetic variation was found [79]. In this study, I further 
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investigated the relationship between genetic variation, molecular variability, and BD exposure 
using the Collaborative Cross (CC), a genetically diverse population of inbred mouse strains with 
haplotypes inherited from the 7 aforementioned mouse strains plus NZO/H1LtJ. With gene 
expression and chromatin accessibility data for mice from 50 CC strains, I assessed global trends in 
variation of these molecular readouts across and within lung, liver, and kidney tissue at three BD 
exposure levels (control and two concentrations of BD). Through this analysis, I report tissue-
specific differences in BD response. With available haplotype data, I performed gene expression 
quantitative trait loci (eQTL) and chromatin accessibility QTL (cQTL) mapping and provide an 
initial characterization of significant associations for each tissue and treatment group. 
 
MATERIALS AND METHODS 
Animals and 1,3-butadiene exposure 
Male Collaborative Cross (CC) mice, obtained from UNC-CH (Chapel Hill, NC, USA), were 
housed in sterilized cages in a temperature-controlled (24°C) room with a 12/12-hr light/dark 
cycle and access to purified water and NIH-31 pelleted diet (Purina Mills, Richmond, IN, USA). Mice 
were randomly assigned to a control group or one of two experimental groups that I denote “625 
ppm” and “1500 ppm”. At approximately 10 weeks old, following a two-week acclimation period, 
mice were placed in cylindrical metal mesh exposure chambers for 6 hours a day, Monday-Friday, 
spanning a two-week period. Exposure chambers for control group mice emitted clean air, and 625 
ppm group and 1500 ppm group exposure chambers contained an average concentration of 
624±72 ppm and 1464±196 ppm of BD gas respectively. Immediately following the final exposure, 
mice were euthanized by exsanguination following deep nembutal (100 mg/kg intraperitoneal 
injection) anesthesia, and lungs, livers, and kidneys were excised, snap-frozen in liquid nitrogen, 
and stored at –80°C for subsequent processing. The animals were treated humanely and with 
regard for alleviation of suffering, and all procedures were approved by the Institutional Animal 
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Care and Use Committee at UNC-CH. Experimental procedures and preparation of mice samples 
were performed by the Rusyn Lab at Texas A&M University (TAMU). 
 
Collaborative Cross reference genomes and transcriptomes 
Alignment and processing of sample data from RNA-seq and ATAC-seq required CC strain-
specific reference genomes and transcriptomes that I denote as “pseudo-genomes” and “pseudo-
transcriptomes” respectively. Pseudo-genomes in FASTA file format and corresponding MOD files 
were downloaded from the CC resource website 
(http://csbio.unc.edu/CCstatus/index.py?run=Pseudo) for Build 37. A Build 37 MOD file provides a 
CC strain-specific mapping between genomic positions from a CC strain’s pseudo-genome and the 
mm9 (C57BL/6J) genomic coordinate space. To construct pseudo-transcriptomes for each CC 
strain, I used the appropriate MOD file to convert mm9 RefSeq gene annotations into strain-specific 
gene annotations. These gene annotations in conjunction with the pseudo-genome FASTA files were 
passed as arguments into the RSEM (v1.2.31) [80] command rsem-prepare-reference with default 
parameter specifications.  
 
RNA-seq and data processing 
Total RNA was isolated from flash-frozen tissue samples using a Qiagen miRNeasy Kit 
(Valencia, CA) according to the manufacturer’s protocol. RNA purity and integrity were evaluated 
using a Thermo Scientific Nanodrop 2000 (Waltham, MA) and an Agilent 2100 Bioanalyzer (Santa 
Clara, CA), respectively. A minimum RNA integrity value of 7.0 was required for RNA samples to be 
used for library preparation and sequencing. Libraries for samples with a sufficient RNA integrity 
value were prepared using the Illumina TruSeq Total RNA Sample Prep Kit (Illumina, Inc., San 
Diego, USA) with ribosomal depletion. Single-end (50bp) sequencing was performed (Illumina 
HiSeq 2500). RNA sample preparations were performed by the Rusyn Lab and sequencing was 
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done by the sequencing facility at TAMU and the UNC-CH High-throughput Sequencing Facility 
(HTSF).  
Following sequencing, reads were filtered to retain only those with a quality score of 20 or 
greater for at least 90 percent of read positions. Additionally, reads with adapter contamination 
were removed using TagDust [81]. For each sequenced RNA sample, reads were mapped to the 
appropriate pseudo-transcriptome using the RSEM command rsem-calculate-expression with STAR 
(v2.5.3a) [82] as the specified aligner (parameter set: --star). RSEM utilizes STAR with alignment 
options that follow ENCODE3 RNA-seq read mapping guidelines 
(https://www.encodeproject.org/pipelines/ENCPL002LSE/).  
 
Gene expression quantification and gene set finalization 
 The RSEM command rsem-calculate-expression used for the RNA-seq read mapping also 
performs gene expression quantification and produces a transcripts per million (TPM) value for 
each gene specified in the pseudo-transcriptome. Samples were grouped by a combination of tissue 
type (liver, lung, and kidney) and treatment status (control, 625 ppm, and 1500 ppm) to produce a 
total of 9 sample groups. TPM values for samples within a group were median ratio normalized 
using DESeq2 [83] to make the values more comparable across samples. A requirement that the 
normalized TPM value must exceed 1 for a gene in at least 5% of the samples within a group was 
applied to exclude genes with sparse expression across samples. As a final filtering step, genes on 
chrY and chrM were excluded. 
 
ATAC-seq and data processing 
Flash frozen tissue samples were pulverized in liquid nitrogen using the BioPulverizer 
(Biospec) to break open cells and allow even exposure of intact chromatin to Tn5 transposase. 
Pulverized material was thawed in glycerol containing nuclear isolation buffer to stabilize nuclear 
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structure [84] and then filtered through Miracloth (Calbiochem) to remove large tissue debris. 
Nuclei were washed and directly used for treatment with Tn5 transposase. Tissue processing was 
performed by the Crawford Lab at Duke University. Single-end (50bp) sequencing was performed 
by UNC-CH HTSF (Illumina HiSeq 2500).  
Following sequencing, reads were filtered to retain only those with a quality score of 20 or 
greater for at least 90 percent of read positions. Additionally, reads with adapter contamination 
were removed using TagDust, and a maximum of 5 read duplicates were allowed. Prior to read 
mapping, a GSNAP database for each pseudo-genome was built using GMAP and the pseudo-
genome FASTA file (parameter set: -k 15, -q 1). For each sample, reads remaining after filtering 
were aligned to the appropriate pseudo-genome using GSNAP (parameter set: -k 15, -m 1, -i 5, --
sampling=1, --trim-mismatch-score=0, --genome-unk-mismatch=1, --query-unk-mismatch=1) [85]. 
Any reads that mapped to more than 4 genomic locations were removed. 
Satellite repetitive elements, regions with high sequence homology to mitochondrial DNA, 
rRNA, and regions on chrX with high sequence homology to chrY are prone to producing artifactual 
signals caused by experimental or technical biases. Consequently, it has been recommended that 
these regions be excluded from sequencing-based analyses [86]. The ENCODE Consortium [15] 
created “blacklists” containing the aforementioned problematic regions for the human genome, and 
blacklists were generated following a similar procedure for the mm9 mouse reference genome. In 
the same manner, pseudo-genome specific blacklists were created by combining RepeatMasker [87] 
annotations and BLAT [88] derived chrX/Y homologous segments and genomic regions in strong 
sequence homology to mitochondrial DNA. These pseudo-genome blacklists were used to remove 
problematic genomic regions from consideration in further analyses. 
Using the CC strain MOD files, mapped reads for each ATAC-seq sample were converted to 
mm9 genomic coordinates to enable direct comparison of data between samples. To account for 
any differences between the pseudo-genome blacklists and the mm9 blacklist, converted reads that 
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mapped to mm9 blacklist regions were removed. Following conversion, all reads aligning to the 
positive strand were offset +5 bp, and all reads aligning to the negative strand were offset by -5 bp. 
These read shiftings account for a previously characterized behavior in the integration of adaptors 
by Tn5 transposase upon DNA binding [89]. 
 
Chromatin accessibility quantification and windowing 
Samples were grouped by a combination of tissue type (liver, lung, and kidney) and 
treatment group (control and 625 ppm) to produce a total of 6 sample groups. For each sample, 
genomic regions representing high chromatin accessibility, i.e. peaks, were determined using the 
peak-calling software F-seq [58] with default parameters. To define an initial common set of 
chromatin regions for between group comparisons, across all sample groups the union set of the 
top 50,000 peaks (ranked by F-seq score) from each sample was derived and overlapping peaks 
were merged, resulting in 310,620 chromatin regions. These peaks were subsequently divided into 
overlapping 300 bp windows as previously described [90]. Briefly, peaks smaller than 300 bp were 
expanded to 300 bp, and for any peak larger than 300 bp, the number of 300 bp windows to 
segment the peak and not exceed its boundaries was determined using an initial overlap constraint 
of 100 bp. If the windows spanned less than 90% of bases within the peak, an additional window 
was added and the overlap was adjusted to produce uniformly spaced windows that exactly 
spanned the peak region. This windowing protocol resulted in 1.8 million windows, and per sample 
read coverage of each window was calculated using BEDTools  coverageBed [91]. 
Read count values for samples within a group were median ratio normalized using DESeq2 
to make the values more comparable across samples. To exclude windows with sparse read counts 
across samples, a filtering procedure similar to that described previously [92] was used. Windows 
were retained if at least 20% of samples within a sample group had high chromatin accessibility. 
High chromatin accessibility was defined as being in the top 20th percentile of normalized read 
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counts of all windows across all samples in a group. Further filtering was done to include only the 
top 5% of windows ranked by total normalized counts across samples in a group. Presumably, 
these windows would more likely contain active regulatory elements while also providing the 
highest power to detect associations. As a final filtering step, regions on chrY and chrM were 
excluded. 
 
Principal component analysis cluster significance testing 
In determining whether two groups of points (or vectors) in a given principal component 
analysis (PCA) transformed space form distinct clusters, I first calculate 1) the Euclidean distance 
between a given point and the centroid of the group for which the point belongs and 2) the 
Euclidean distance between a given point and the centroid of the group for which the point does not 
belong. These are referred to as within group and between group distances respectively. The 
distributions of within group and between group distances were compared using a Wilcoxon rank-
sum test with α≤0.05 to determine if there exists a statistically significant difference between the 
distances, indicating significant clustering. 
 
Differential gene expression analysis 
The number of differentially expressed genes between treatment groups was determined 
using DESeq2. The 625 ppm and 1500 ppm groups were combined to represent one BD exposure 
group. Both the control and BD exposed group were reduced to samples representing only the 
strains in common between both groups to mitigate inconsistencies in genetic background. 
Expected counts estimated by RSEM were used to generate a matrix of gene abundances. Genes 
with no expected counts across samples were removed prior to analysis by DESeq2. To mitigate the 
influence of technical variation, batch and sequencing center were included as covariates in the 
DESeq2 model.  
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Haplotype reconstruction and segmentation for eQTL and cQTL analysis 
Diplotype probabilities for each CC strain in this study were obtained from the CC resource 
database (http://csbio.unc.edu/CCstatus/index.py?run=FounderProbs) for genome version B37. 
These haplotype reconstructions were previously calculated using an HMM model for genotype 
array data [93]. The haplotype reconstructions provide probabilities of a genomic region being 
inherited from each of the 8 founder strains represented as probabilities for 36 genotype calls (8 
homozygous and 28 heterozygous founder strain calls) for each genotype array marker. These 
probabilities were converted into haplotype dosages, i.e., the expected number of haplotypes. Let G 
be a symmetric matrix of genotype call probabilities for a marker m and Gij be the genotype call 
probability for genotype ij comprised of two founder strain haplotypes i,j∈{A,B,C,D,E,F,G,H}. Note 
that in this case Gij and Gji are considered equivalent. The haplotype dosage calculation for founder 
strain haplotype k and marker m is  
 
 
To reduce the computational burden of testing for haplotype-phenotype associations at each 
genotype marker, segmentation analysis was performed [94]. Briefly, since array marker densities 
exceed the total density of recombinations in the CC population, haplotype segment boundaries 
were redefined based on transitions between highest dosage haplotype.  For each CC strain, a 
segment breakpoint was defined at a genotype marker whenever the highest dosage haplotype 
differed from the previous marker. The union set of breakpoints across all 50 CC strains in this 
study was used to construct the final segment boundaries, resulting in 4,970 segments. Segments 
on chrY and chrM were excluded. The mean and median segment sizes were 0.48 and 0.22 Mb 
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respectively with the largest segment size being 11.47 Mb. For each haplotype, dosages were 
averaged for all markers within a segment. Using a consolidated set of segments for QTL analysis 
has been shown to produce essentially identical results to using a full set of genotype markers 
while simultaneously providing improvements in computational efficiency [94].  
 
eQTL and cQTL analysis workflow 
For both eQTL and cQTL analysis, the general approach for detecting haplotype-phenotype 
associations is the same, but the analyses differ in the phenotypes being assessed. For clarity and 
simplicity, the methodology here is elaborated in terms of gene expression (eQTL) for a single 
phenotype (gene) and haplotype segment but applies to chromatin windows (cQTL) as well. 
Associations are identified using a modified regression on probabilities (ROP) framework [95,96]. 
Normalized TPM values transformed using a rank-based inverse normal transform were regressed 
on averaged haplotype dosages. Sequencing center and batch were included as covariates. An F-test 
was performed to assess model fit with the null model specified to exclude haplotype dosages. This 
procedure was applied to all genes for all segments, and statistical significance of p-values was 
determined at a 5% False Discovery Rate (FDR) using the R package qvalue [97]. 
 
RESULTS 
Experimental Design 
A major goal of this study was to characterize the impact of genetic variability and BD 
exposure on gene expression and chromatin accessibility. To do so, mice representing 50 
Collaborative Cross (CC) mouse strains were assigned into three groups that we denote as 
“control”, “625 ppm”, and “1500 ppm”. Each group contained one mouse for a given strain.  The 
control group mice were placed in exposure chambers circulating clean air for 6 hours a day, five 
days per week, for two weeks. The 625 ppm and 1500 ppm groups were placed in exposure 
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chambers with approximately 625 ppm and 1500 ppm concentrations of BD respectively. RNA-seq 
was performed on lung, liver, and kidney tissue for mice in each group as well as ATAC-seq for mice 
in the control and 625 ppm groups (Figure 3.1). The experiments were designed to maximize the 
number of strains represented in each group, but due to limitations and experiment-specific factors, 
RNA-seq and ATAC-seq data were not available for all tissues across all strains and groups (Table 
3.1). After data processing, 35 strains were shared for both assays across all tissues and groups, 37 
strains across all tissues and groups for RNA-seq, 40 strains across all tissues and groups for ATAC-
seq, 43 strains across tissues in the ATAC-seq control group, 47 strains across tissues in the ATAC-
seq 625 ppm group, 49 strains across tissues in the RNA-seq control group, 43 strains across 
tissues in the RNA-seq 625 ppm group, and 44 strains across tissues in the RNA-seq 1500 ppm 
group. 
 
Tissue-type strongly contributes to gene expression variation between samples 
To identify variables that prominently contribute to overall gene expression variability, I performed 
principal components analysis (PCA) on the gene expression profiles, derived from RNA-seq, of 
each individual in our study across all treatment groups and tissues. Principal Components (PCs) 1 
and 2 contributed to 35.7% and 17.9% of the total variance respectively with the remaining 46.4% 
of total variance distributed among the remaining 406 PCs (Figure 3.2). Visualization of PCs 1-4 
individually as Gaussian kernel density estimates and pairwise as scatterplots showed a clear 
separation of samples by tissue type in PCs 1 and 2 (Figure 3.3). PCs 3 and 4 did not exhibit 
separation by tissue, but did portray partial clustering by BD exposure status (Figure 3.4).  To 
assess whether the clustering by BD exposure status was statistically significant, I applied a 
Wilcoxon rank-sum test to compare distributions consisting of the between group and within group 
distances to the group centroids using PCs 3 and 4 (see Materials & Methods). The p-value obtained 
provides support for a significant separation between clusters on PCs 3 and 4. (p < 2.2e-16). 
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Within-tissue gene expression variation reveals BD exposure associated effects 
 Because between-tissue gene expression variability showed more prominent tissue 
associated variation than BD associated effects, I performed PCA of gene expression profiles from 
all treatment groups for each tissue independently to investigate whether BD exposure contributed 
to noticeable variation within a tissue. Relative to the PCA across all three tissues, PC 1 for each 
tissue contributed less to the total variance with percent contributions being 9.7%, 8.5%, and 8.6% 
for lung, liver, and kidney respectively (Figure 3.5). Visualization of PCs for each tissue in a similar 
manner as the across-tissue PCA revealed a distinct separation of samples by BD exposure status in 
lung and liver but not in kidney on PCs 1 and 2 (Figures 3.6, 3.7, and 3.8). For samples in kidney, 
clusters associated with BD exposure became apparent on PCs 4 and 5. Statistical significance of the 
perceived groupings within each tissue were evaluated by the Wilcoxon rank-sum test as with the 
across tissue PCA analysis. For the clustering assessment of lung samples, PCs 1 and 2 showed a 
statistically significant separation between groups (p < 2.2e-16), as did PC 1 for liver samples (p < 
2.2e-16) and PCs 4 and 5 for kidney samples (p < 2.2e-16). The clustering of kidney samples by BD 
exposure status occurred at later PCs relative to the PCA of lung and liver samples, suggesting that 
gene expression changes in kidney tissue in response to BD are not as prominent as in lung and 
liver tissue. Differential expression analysis was conducted using DESeq2 to determine the number 
of differentially expressed genes in the three tissues between control and BD exposed mice. Based 
on observations from PCA, the expected outcome was that fewer genes would be differentially 
expressed in kidney tissue compared to lung and liver, and this was observed. In kidney 3,639 
genes were significantly differentially expressed between control and BD exposed samples whereas 
lung and liver had 6,936 and 6,512 differentially expressed genes respectively (FDR 0.05, Figure 
3.9). These results in conjunction with the PCA show that BD exposure associated effects on gene 
expression are more pronounced in lung and liver tissue than kidney. 
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Chromatin accessibility differences by tissue type are more pronounced than BD exposure 
associated variation. 
 From PCA of gene expression profiles, differences between tissues were noted as the 
strongest source of variation. To assess whether this applied to chromatin region accessibility as 
well, PCA was performed on chromatin accessibility profiles constructed from ATAC-seq data for 
each sample across all treatment groups and tissues. Initially, the top 5% of 300 bp chromatin 
windows ranked by accessibility (total read counts) were analyzed (see Materials & Methods). A 
substantial amount of the total variance was captured by PC 1 (52.5%) with a sharp decrease to 
6.9% explained by PC 2 (Figure 3.10). Visualization of PCs 1-5 as previously done for the gene 
expression PCA showed a less distinct separation of samples by tissue (Figure 3.11). Additionally, 
no separation of samples by treatment group was visually apparent (Figure 3.12). Because the top 
5% of chromatin windows may be capturing many sites commonly accessible across tissues, PCA 
was also applied to the top 50% most accessible chromatin windows. Using a broader set of 
chromatin windows reduced the variance contribution of PC 1 to 32%, but increased the variance 
explained by PC 2 to 15.2%. The remaining PCs each contributed less than 1% (Figure 3.10). 
Interestingly, PCs 1 and 2 produce a stark separation of samples by tissue type that was less 
pronounced using the top 5% of chromatin windows, but samples still do not cluster by treatment 
group within the top 5 PCs (Figures 3.13 and 3.14). The observations made through comparison of 
the top 5% and top 50% of chromatin windows suggest that the most accessible regions are more 
likely to be active across tissues. In both cases, BD exposure associated variation did not appear to 
produce sample clusters. 
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Within-tissue chromatin accessibility variation captures BD exposure associated effects in lung 
and liver 
 To investigate whether samples within each tissue segregate by BD exposure status, PCA of 
chromatin accessibility profiles was performed separately for each tissue. Both the top 5% and top 
50% most accessible chromatin windows were analyzed. Similar to the across tissue PCA, PC 1 for 
the top 5% of windows in each tissue comprised more variance than in the top 50% of windows 
(34.7-45.6% vs. 9.4-13.3%; Figures 3.15 and 3.16). In lung, PCs 3 and 4 for both sets of windows 
showed potential clustering by treatment group (Figures 3.17 and 3.18), but evaluation of clusters 
by a Wilcoxon rank-sum test only showed significant grouping for the top 50% (top 5% set p = 
0.054; top 50% set p = 1.83e-12). From individual and pairwise visualization of the top 5 PCs, liver 
and kidney samples did not clearly separate by treatment status for the top 5% most accessible 
chromatin windows (Figures 3.19 and 3.21), and evaluation of their sample to centroid distances as 
aforementioned confirmed a lack of statistically significant grouping (liver p = 0.41; kidney p = 
0.07). However, the top 50% set for liver samples produced a significant p-value on PCs 1-5 (p = 
1.58e-5; Figure 3.20), but the p-value for the kidney top 50% set still did not reach significance (p = 
0.1; Figure 3.22). These observations of chromatin accessibility variation reflect the general pattern 
seen with gene expression profiles where lung and liver appear to be more strongly affected by BD 
exposure than kidney tissue. 
 
Identification of local and distal gene expression QTLs in CC mice 
 The public availability of CC genotype data allowed for me to investigate how genetic 
variation influences variability in transcriptional output. Treating gene expression as a molecular 
quantitative trait and regressing on haplotype dosages of genomic segments, eQTL mapping was 
performed using RNA-seq data for each treatment group (control, 625 ppm BD exposure, 1500 ppm 
BD exposure) in lung, liver, and kidney tissue. Because the numbers of CC strains in each group 
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were not consistent, I reduced the strains in each group to the universal set of 35 strains in 
common. The total number of control group eQTLs detected in lung, liver, and kidney were 400, 
505, and 869 respectively (FDR 0.05; Table 3.2; Figures 3.24-3.26). When comparing the genomic 
locations of segments to the positions of their significantly associated genes (eGenes), in all three 
tissues most associations were local which we define as 10 Mb from the gene transcription start 
site (TSS; Figure 3.23). This observation is consistent with previous eQTL studies in both mice and 
human [94,98]. For lung, 34 of the 67 eGenes had local associations and 36 eGenes paired with a 
distal segment. Of the 168 eGenes in liver, I observed 101 local and 82 distal associations. Kidney 
possessed the highest number of eGenes identified at 213 of which 105 paired with local segments 
and 124 had distal associations. 
 In the 625 ppm group, 505 lung eQTLs were found with 97 eGenes (FDR 0.05). Of those 
eGenes 58 were from local eQTLs, and 44 were associated with distal segments. In liver 842 eQTLs 
were detected for 102 eGenes with 44 pairing with local and 65 pairing with distal segments. Lastly, 
for the 2,336 kidney eQTLs observed, 162 of the 283 eGenes had local associations and 136 were 
distal (Table 3.2; Figures 3.27-3.29). Compared to the 625ppm group, the total number of 1500 
ppm group eQTLs identified increased for all tissues to 869 (lung), 1,803 (liver), and 3,523 
(kidney).  The number of eGenes was 114 (66 local; 55 distal), 216 (128 local; 104 distal), and 417 
(255 local; 188 distal) in lung, liver, and kidney respectively (Table 3.2; Figures 3.30-3.32). Relative 
to the control group, the number of eQTLs identified increased for each tissue in both the 625ppm 
and 1500 ppm group with the exception of the liver 625 ppm group. In comparing the distances of 
associations, in all treatment groups and tissues most of the associations were within 10 Mb (Figure 
3.23). 
 Within a treatment group, the fraction of eQTLs that overlapped between tissues ranges 
from 0.04 to 0.21 when considering all eQTLs (FDR 0.05; Figure 3.33). Across treatment groups for 
the same pairwise comparisons, the pattern of overlaps remained fairly consistent with the largest 
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change being 0.07. In each treatment group, the fraction of lung and liver eQTLs overlapping kidney 
was the highest. When considering local and distal eQTL overlaps separately, local eQTL overlaps 
were more concordant than distal within a treatment group (Figure 3.34). Between treatment 
groups within a tissue, the fraction of concordant eQTLs ranged from 0.1 to 0.26 for lung, 0.13 to 
0.34 for liver, and 0.18 to 0.39 for kidney (Figure 3.33). Similar to the overlap within a treatment 
group and between tissues, a breakdown into local and distal eQTLs showed that overall, local 
eQTLs more consistently appeared across treatment groups than distal eQTLs (Figure 3.35). 
Observations that local regulation of gene expression within a tissue is the most consistent despite 
BD exposure supports the notion that tissue effects of the local regulatory landscape are more 
prominent than treatment effects. However, the consistency across treatment groups varies by 
tissue with kidney being the most consistent and lung being the least, suggesting that treatment 
effects are relatively stronger in lung. I also note that the low level of similarity between tissues 
suggests more disparate regulatory landscapes between tissues. In all cases, distal eQTLs appear 
less stable than local eQTLs, which could be related to difficulties in distal eQTL detection due to the 
small sample size and smaller effect sizes relative to local eQTLs. 
 
Identification of local and distal chromatin accessibility QTLs in CC mice 
 In addition to the eQTL mapping, cQTL mapping was performed for the control and 625 
ppm BD exposure group for lung, liver, and kidney tissues. Accessible chromatin regions often 
represent nucleosome-depleted, active gene regulatory elements [41], thus characterizing how 
genetic variation impacts chromatin accessibility provides an additional layer of information to 
complement eQTLs. Again, using the universal set of 35 CC strains, the control group cQTL mapping 
resulted in 3,328 lung, 88 liver, and 5,700 kidney cQTLs (FDR 0.05; Table 3.3, Figures 3.37-3.39). 
When assessing the distance of cQTL associations, in all three tissues the majority of cQTLs were 
local (within 10 Mb; Figure 3.36). For lung, 72 of the 325 cQTL chromatin windows had local 
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associations, and 256 chromatin windows paired with a distal segment. Of the 15 cQTL chromatin 
windows in liver, 7 had local and 11 had distal associations. In kidney, 353 cQTL chromatin 
windows were identified of which 105 paired with local segments and 257 had distal associations. 
In the 625 ppm group, 8,472 lung cQTLs were found with 594 chromatin windows (FDR 0.05). Of 
those windows 93 had local associations, and 510 were associated with distal segments. 
Surprisingly, no cQTLs were considered significant at FDR 0.05 for liver. The lack of associations 
may be due to a combination of small sample size, limited chromatin windows tested, and less 
genetic variation associated with chromatin accessibility for our mouse strains, ultimately resulting 
in limited power to discover cQTLs (see Discussion). The number of kidney cQTLs decreased to 
2,532 compared to the 5,700 detected in the control group. I observed 87 of the 238 chromatin 
windows with local associations and 164 with distal associations (Table 3.3, Figures 3.40-3.42). 
Similar to the control group results, most cQTL associations were shorter than 10 Mb, despite more 
chromatin windows having distal associations than local associations (Figure 3.36). 
 When assessing the cQTL overlap within a treatment group and between tissues, for the 
control group, 41% of lung cQTLs overlapped with kidney cQTL (FDR 0.05; Figure 3.42), but the 
percentage decreased to 12% for the 625 ppm group. Conversely, the percentage of kidney cQTLs 
that overlap lung cQTLs changes from 24% to 39% between treatment groups. This inverse 
relationship of lung and kidney between treatment groups appears related to the relationship 
between total cQTLs discovered, where detected lung cQTLs increased 2.5 fold upon BD exposure, 
and kidney cQTLs decreased 56%. This suggests that increasing the number of cQTLs detected will 
generally decrease the overlap fraction. When looking more specifically at local versus distal cQTL 
overlap, the control group showed similar local and distal cQTL overlap between lung and kidney, 
but the 625 ppm group exhibited no clear patterns. Notably, distal kidney cQTLs overlapped lung 
cQTLs by 47% (Figure 3.43). 
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 In the eQTL analysis, overlaps within a tissue and between treatment groups were more 
consistent than within a treatment group and between tissues. The relationship is less clear for the 
cQTL results, but the highest overlaps were still observed within a tissue and between treatment 
groups (Figure 3.42). Breakdown by local and distal cQTLs revealed that more lung control group 
cQTLs overlapped with the 625 ppm group than vice versa for both local and distal cQTLs. The 
opposite relationship was observed in kidney. This further supports my observation that increasing 
the number of cQTLs detected will decrease the overlap fraction and may be contributing to a less 
apparent pattern in the cQTL results compared to the eQTL results. 
 
Lung cQTL hotspots show founder strain specific phenotype clustering 
 The genome-wide plots of lung cQTL associations in both treatment groups produced 
visibly pronounced “hotspots” where a genomic locus was enriched for associations with chromatin 
windows genome-wide (Figures 3.37 and 3.40). The control group hotspot fell on chr14, and the 
625 ppm hotspot was observed on chr13. Although this has not been previously characterized for 
cQTLs in the CC population, past studies have reported the occurrence of eQTL hotspots [99,100]. 
To better understand if a particular CC founder strain is driving the associations seen within the 
lung control group hotspot, the control mice were ordered by level of lung chromatin accessibility 
for chromatin windows chr14:76244575-76244874 and chr9:24956096-24956395 and haplotype 
dosages were visualized for haplotype segment UNC24188333-UNC24192133 (chr14:69792831-
70034137, Figure 3.45). These chromatin windows produced the most significant local and distal 
associations for UNC24188333-UNC24192133. These cQTLs exhibited clustering of lower 
chromatin accessibility values for founder haplotype NOD/ShiLtJ and higher values for NZO/HiLtJ. 
The same visualization was applied for segment UNC23481318-UNC23486670 (chr13:118864010-
119236105) and 2 significantly associated chromatin windows for the 625 ppm group cQTL 
mapping (Figure 3.46). For both associations, the C57BL/6J, NOD/ShiLtJ, and NZO/HiLtJ haplotypes 
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showed distinct phenotype values that spanned the spectrum of measured chromatin accessibility. 
Although more hotspot associations need to be evaluated, these initial observations suggest that 
these haplotypes would be good candidates for further investigations into which haplotypes are 
driving the hotspot associations.  
 As noted previously, a moderate number of distal 625ppm kidney cQTLs overlapped with 
lung cQTLs. Upon assessing the locations of these overlapping cQTLs, I identified another hotspot 
location on chr8 shared between these two tissues (Figure 3.47). For two chromatin windows, 
chr8:19981785-19982084 and chr8:197000103-19700402, chromatin accessibility portrayed clear 
clustering by founder strain haplotype at segment JAX00663067 (chr8:23562597). Specifically, 
CAST/EiJ and PWK/PhJ showed the highest phenotype values, and WSB/EiJ had the lowest values. 
The contrast between the three haplotypes gives evidence for their strong effect on chromatin 
accessibility in these chromatin regions. 
 
DISCUSSION 
In this study I sought to characterize variability in gene regulation and transcription in 
three mouse tissues. In the GTEx pilot analysis, samples largely grouped by tissue based on 
hierarchical clustering of gene expression [24]. Through multi-tissue PCA, I made the same 
conclusion. Tissue type had the largest effect on both gene expression and chromatin accessibility. 
Interestingly, tissue type clustering was less apparent in the ATAC-seq samples when considering 
the top 5% of chromatin windows compared to the top 50%. This observation suggests that many 
of the more accessible chromatin regions were common across tissues, and inclusion of more 
windows incorporated more distal, tissue-specific chromatin regions. When evaluating the impact 
of BD exposure on gene expression and chromatin, I witnessed different levels of response between 
tissues. Lung presented the largest number of differentially expressed genes between control and 
BD exposed mice followed by liver. Both lung and liver exhibited greater than 1.7 times the number 
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of differentially expressed genes compared to kidney. Lung and liver also exhibited the more 
notable variation in chromatin accessibility by treatment status compared to kidney. These 
observations align with previous findings of significant epigenetic changes in lung and liver but not 
kidney [69]. Given the more dynamic response of lung and liver gene expression to BD, further 
investigation of these genes may elucidate important regulatory pathways in BD metabolism and 
BD-related carcinogenesis. 
An important advantage of the experimental design for this study was the use of CC mice. 
Being that the CC population consists of recombinant inbred mouse strains, CC mice with the same 
genetic background could be studied in three different treatment environments. Simultaneously, 
the representation of multiple CC strains within a treatment group provided genetic diversity that 
was utilized for eQTL and cQTL mapping. In the eQTL analysis, eQTLs were detected in all three 
tissues with most of the associations being local. In comparing the eQTLs identified for each tissue 
and treatment group, tissue specificity was noted by the higher overall overlap of eQTLs within a 
tissue and across treatment groups than between tissues and within a treatment group. In line with 
the aforementioned observation that lung has the most dynamic gene expression response to BD, 
eQTLs in lung were the least consistent across treatment groups relative to liver and kidney eQTLs.  
Although the reproducible genetic diversity of the CC was advantageous in characterizing 
eQTLs, the small number of samples used in the cQTL mapping decreased power to detect 
associations. The choice to use a set of 35 CC strains common across all tissue and treatment groups 
was motivated by concerns that additional genetic variation from a CC strain unique to a specific 
group would create less comparable results. Unfortunately, a consequence of this decision was the 
discovery of only a handful of liver cQTLs. To assess the impact of including the additional 13 CC 
strains, I performed cQTL mapping for the liver control group utilizing the 48 mice/strains 
available for that group. Using an FDR 0.05 significance threshold, 7,991 cQTLs were detected as 
opposed to the 88 identified with a sample size of 35. The drastic difference reflects a significant 
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loss in power to detect genotype related chromatin accessibility variation by excluding the 13 CC 
strains in cQTL mapping. Nevertheless, I still identified thousands of lung and kidney cQTLs with 
the reduced set of CC strains. As with the eQTL analysis, most associations were local, but cQTL 
hotspots were observed in lung and kidney despite the expectation that distal cQTL detection 
would be underpowered. To my knowledge, these hotspots are the first to be characterized for 
cQTLs in mice. Observations of haplotype dosages for select associations in each of the hotspots 
revealed likely founder strain haplotypes driving the chromatin accessibility differences. However, 
to better infer haplotype effects, more rigorous follow-up analyses need to be done such as the 
application of Diploffect, a Bayesian model described in [96] that estimates haplotype effects while 
accounting for uncertainty in the diplotype probability estimates. 
 In summary, these results serve as an initial characterization of tissue specific, genetic, and 
BD exposure related variability to gene expression and chromatin accessibility. I observed that all 
three factors play a role in gene regulatory differences, providing a basis for any or all factors being 
further investigated more in-depth.  Through this work, I also demonstrated the strengths and 
weaknesses of the experimental design that will be informative for future studies that take 
advantage of the Collaborative Cross. As a whole, these results contribute to the growing body of 
studies that seek to better understand the relationship between genetics, gene regulation, 
environment, and phenotype. 
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Figure 3.1.   Experimental design overview. Male mice representing 50 CC strains were assigned 
to one of three exposure groups. After a two-week treatment period, lung, liver, and kidney tissue 
were obtained from each mouse which were processed for sequencing. ATAC-seq was not 
performed on tissue from the 1500 ppm group mice. 
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Figure 3.2.   Multi-tissue gene expression PCA scree plot. Percent of variance explained by the 
top 10 PCs for PCA of gene expression profiles for all samples. 
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Figure 3.3.   Multi-tissue gene expression PCA plot colored by tissue type. PCA plot for the top 
4 PCs from PCA of gene expression profiles for all samples. Diagonal subplots are kernel density 
estimates of sample values for a given PC. Off diagonal subplots are scatterplots of all pairwise 
comparisons of PCs 1-4. 
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Figure 3.4.   Multi-tissue gene expression PCA plot colored by treatment status. PCA plot for 
the top 4 PCs from PCA of gene expression profiles for all samples. Diagonal subplots are kernel 
density estimates of sample values for a given PC. Off diagonal subplots are scatterplots of all 
pairwise comparisons of PCs 1-4. 
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Figure 3.5.   Per-tissue gene expression PCA scree plots. Percent of variance explained by the 
top 10 PCs for PCA of gene expression profiles for A) Lung, B) Liver, and C) Kidney samples. 
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Figure 3.6.   Lung gene expression PCA plot. PCA plot for the top 5 PCs from PCA of gene 
expression profiles for lung samples. Diagonal subplots are kernel density estimates of sample 
values for a given PC. Off diagonal subplots are scatterplots of all pairwise comparisons of PCs 1-5. 
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Figure 3.7.   Liver gene expression PCA plot. PCA plot for the top 5 PCs from PCA of gene 
expression profiles for liver samples. Diagonal subplots are kernel density estimates of sample 
values for a given PC. Off diagonal subplots are scatterplots of all pairwise comparisons of PCs 1-5. 
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Figure 3.8.   Kidney gene expression PCA plot. PCA plot for the top 5 PCs from PCA of gene 
expression profiles for kidney samples. Diagonal subplots are kernel density estimates of sample 
values for a given PC. Off diagonal subplots are scatterplots of all pairwise comparisons of PCs 1-5. 
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Figure 3.9.   Differentially expressed genes by tissue. Number of differentially expressed genes 
between control and BD exposed treatment groups detected by DESeq2 at FDR 0.05 for lung, liver, 
and kidney tissue samples.  
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Figure 3.10.   Multi-tissue chromatin accessibility PCA scree plots. Percent of variance 
explained by the top 10 PCs for PCA of chromatin accessibility profiles for all samples using A) the 
top 50% of chromatin windows ranked by chromatin accessibility and B) the top 5% of chromatin 
windows ranked by chromatin accessibility. 
A 
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Figure 3.11.   Multi-tissue top 5% chromatin windows PCA plot colored by tissue type. PCA 
plot for the top 5 PCs from PCA of chromatin accessibility profiles for all samples using the top 5% 
of chromatin windows ranked by accessibility. Diagonal subplots are kernel density estimates of 
sample values for a given PC. Off diagonal subplots are scatterplots of all pairwise comparisons of 
PCs 1-5. 
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Figure 3.12.   Multi-tissue top 5% chromatin windows PCA plot colored by treatment status. 
PCA plot for the top 5 PCs from PCA of chromatin accessibility profiles for all samples using the top 
5% of chromatin windows ranked by accessibility. Diagonal subplots are kernel density estimates 
of sample values for a given PC. Off diagonal subplots are scatterplots of all pairwise comparisons of 
PCs 1-5. 
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Figure 3.13.   Multi-tissue top 50% chromatin windows PCA plot colored by tissue type. PCA 
plot for the top 5 PCs from PCA of chromatin accessibility profiles for all samples using the top 50% 
of chromatin windows ranked by accessibility. Diagonal subplots are kernel density estimates of 
sample values for a given PC. Off diagonal subplots are scatterplots of all pairwise comparisons of 
PCs 1-5. 
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Figure 3.14.   Multi-tissue top 50% chromatin windows PCA plot colored by treatment status. 
PCA plot for the top 5 PCs from PCA of chromatin accessibility profiles for all samples using the top 
50% of chromatin windows ranked by accessibility. Diagonal subplots are kernel density estimates 
of sample values for a given PC. Off diagonal subplots are scatterplots of all pairwise comparisons of 
PCs 1-5. 
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Figure 3.15.   Per-tissue top 5% chromatin windows PCA scree plots. Percent of variance 
explained by the top 10 PCs for PCA of chromatin accessibility profiles for all samples using the top 
5% of chromatin windows ranked by chromatin accessibility in A) lung, B) liver, and C) kidney. 
A 
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Figure 3.16.   Per-tissue top 50% chromatin windows PCA scree plots. Percent of variance 
explained by the top 10 PCs for PCA of chromatin accessibility profiles for all samples using the top 
50% of chromatin windows ranked by chromatin accessibility in A) lung, B) liver, and C) kidney. 
A 
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Figure 3.17.   Lung top 5% chromatin windows PCA plot. PCA plot for the top 5 PCs from PCA of 
chromatin accessibility profiles for lung samples using the top 5% of chromatin windows ranked by 
accessibility. Diagonal subplots are kernel density estimates of sample values for a given PC. Off 
diagonal subplots are scatterplots of all pairwise comparisons of PCs 1-5. 
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Figure 3.18.   Lung top 50% chromatin windows PCA plot. PCA plot for the top 5 PCs from PCA 
of chromatin accessibility profiles for lung samples using the top 50% of chromatin windows 
ranked by accessibility. Diagonal subplots are kernel density estimates of sample values for a given 
PC. Off diagonal subplots are scatterplots of all pairwise comparisons of PCs 1-5. 
105 
 
 
 
Figure 3.19.   Liver top 5% chromatin windows PCA plot. PCA plot for the top 5 PCs from PCA of 
chromatin accessibility profiles for liver samples using the top 5% of chromatin windows ranked by 
accessibility. Diagonal subplots are kernel density estimates of sample values for a given PC. Off 
diagonal subplots are scatterplots of all pairwise comparisons of PCs 1-5. 
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Figure 3.20.   Liver top 50% chromatin windows PCA plot. PCA plot for the top 5 PCs from PCA 
of chromatin accessibility profiles for liver samples using the top 50% of chromatin windows 
ranked by accessibility. Diagonal subplots are kernel density estimates of sample values for a given 
PC. Off diagonal subplots are scatterplots of all pairwise comparisons of PCs 1-5 
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Figure 3.21.   Kidney top 5% chromatin windows PCA plot. PCA plot for the top 5 PCs from PCA 
of chromatin accessibility profiles for kidney samples using the top 5% of chromatin windows 
ranked by accessibility. Diagonal subplots are kernel density estimates of sample values for a given 
PC. Off diagonal subplots are scatterplots of all pairwise comparisons of PCs 1-5. 
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Figure 3.22.   Kidney top 50% chromatin windows PCA plot. PCA plot for the top 5 PCs from 
PCA of chromatin accessibility profiles for kidney samples using the top 50% of chromatin windows 
ranked by accessibility. Diagonal subplots are kernel density estimates of sample values for a given 
PC. Off diagonal subplots are scatterplots of all pairwise comparisons of PCs 1-5. 
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Figure 3.23.   Distance of eQTL associations. Genomic distance between a gene TSS and its 
significantly associated haplotype segment for each detected eQTL (FDR 0.05) compared to the 
eQTL p-value. Each subplot is for eQTLs identified in a specific treatment group and tissue. 
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Figure 3.24. Lung control group eQTL map. Genome-wide scatterplot comparing the location of a 
segment to the position of its significantly associated gene for identified eQTLs (FDR 0.05) 
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Figure 3.25. Liver control group eQTL map. Genome-wide scatterplot comparing the location of a 
segment to the position of its significantly associated gene for identified eQTLs (FDR 0.05) 
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Figure 3.26. Kidney control group eQTL map. Genome-wide scatterplot comparing the location 
of a segment to the position of its significantly associated gene for identified eQTLs (FDR 0.05) 
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Figure 3.27. Lung 625 ppm group eQTL map. Genome-wide scatterplot comparing the location of 
a segment to the position of its significantly associated gene for identified eQTLs (FDR 0.05) 
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Figure 3.28. Liver 625 ppm group eQTL map. Genome-wide scatterplot comparing the location 
of a segment to the position of its significantly associated gene for identified eQTLs (FDR 0.05) 
 
 
115 
 
Figure 3.29. Kidney 625 ppm group eQTL map. Genome-wide scatterplot comparing the location 
of a segment to the position of its significantly associated gene for identified eQTLs (FDR 0.05) 
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Figure 3.30. Lung 1500 ppm group eQTL map. Genome-wide scatterplot comparing the location 
of a segment to the position of its significantly associated gene for identified eQTLs (FDR 0.05) 
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Figure 3.31. Liver 1500 ppm group eQTL map. Genome-wide scatterplot comparing the location 
of a segment to the position of its significantly associated gene for identified eQTLs (FDR 0.05) 
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Figure 3.32. Kidney 1500 ppm group eQTL map. Genome-wide scatterplot comparing the 
location of a segment to the position of its significantly associated gene for identified eQTLs (FDR 
0.05) 
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Figure 3.33.   Total fraction of overlapping eQTLs. Pairwise comparisons of the fraction of 
significant eQTLs (FDR 0.05) that overlap A-C) between tissues within a treatment group and D-F) 
between treatment groups within a tissue. The row label of each matrix signifies the group used as 
the denominator of a given fraction in a comparison. Colors denote degree of overlap. 
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Figure 3.34.   Fraction of overlapping local and distal eQTLs across tissues. Pairwise 
comparisons of the fraction of significant eQTLs (FDR 0.05) that overlap between tissues within a 
treatment group for A-C) local and D-F) distal eQTLs. Local eQTL is defined as an association less 
than 10 Mb in length. The row label of each matrix signifies the group used as the denominator of a 
given fraction in a comparison. Colors denote degree of overlap. 
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Figure 3.35.   Fraction of overlapping local and distal eQTLs across treatment groups. 
Pairwise comparisons of the fraction of significant eQTLs (FDR 0.05) that overlap between 
treatment groups within a tissue for A-C) local and D-F) distal eQTLs. Local eQTL is defined as an 
association less than 10 Mb in length. The row label of each matrix signifies the group used as the 
denominator of a given fraction in a comparison. Colors denote degree of overlap. 
A C B 
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Figure 3.36.   Distance of cQTL associations. Genomic distance between a chromatin window 
start position and its significantly associated haplotype segment for each detected cQTL (FDR 0.05) 
compared to the cQTL p-value. Each subplot is for cQTLs identified in that treatment group and 
tissue. The liver 625 ppm group is not shown due to no significant cQTLs discovered. 
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Figure 3.37. Lung control group cQTL map. Genome-wide scatterplot comparing the location of a 
segment to the position of its significantly associated chromatin window for identified cQTLs (FDR 
0.05). 
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Figure 3.38.   Liver control group cQTL map. Genome-wide scatterplot comparing the location of 
a segment to the position of its significantly associated chromatin window for identified cQTLs 
(FDR 0.05). 
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Figure 3.39.   Kidney control group cQTL map. Genome-wide scatterplot comparing the location 
of a segment to the position of its significantly associated chromatin window for identified cQTLs 
(FDR 0.05). 
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Figure 3.40.   Lung 625 ppm group cQTL map. Genome-wide scatterplot comparing the location 
of a segment to the position of its significantly associated chromatin window for identified cQTLs 
(FDR 0.05). 
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Figure 3.41.   Kidney 625 ppm group cQTL map. Genome-wide scatterplot comparing the 
location of a segment to the position of its significantly associated chromatin window for identified 
cQTLs (FDR 0.05). 
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Figure 3.42.   Total fraction of overlapping cQTLs. Pairwise comparisons of the fraction of 
significant cQTLs (FDR 0.05) that overlap A,B) between tissues within a treatment group and C,D) 
between treatment groups within a tissue. The row label of each matrix signifies the group used as 
the denominator of a given fraction in a comparison. Colors denote degree of overlap. 
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Figure 3.43.   Fraction of overlapping local and distal cQTLs across tissues. Pairwise 
comparisons of the fraction of significant cQTLs (FDR 0.05) that overlap between tissues within a 
treatment group for A,B) local and C,D) distal associations. Local associations are defined as being 
less than 10 Mb in length. The row label of each matrix signifies the group used as the denominator 
of a given fraction in a comparison. Colors denote degree of overlap. 
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Figure 3.44.   Fraction of overlapping local and distal cQTLs across treatment groups. 
Pairwise comparisons of the fraction of significant cQTLs (FDR 0.05) that overlap between 
treatment groups within a tissue for A,B) local and C,D) distal associations. Local associations are 
defined as being less than 10 Mb in length. The row label of each matrix signifies the group used as 
the denominator of a given fraction in a comparison. Colors denote degree of overlap. 
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Figure 3.45.   Lung control group hotspot haplotype dosages. Haplotype dosages at segment 
UNC24188333.UNC24192133 (chr14:69792831-70034137) for each mouse arranged by 
chromatin accessibility phenotype values at chromatin windows A) chr14:76244575-76244874 
and B) chr9:24956096-24956395. Each column corresponds to the phenotype value for a mouse, 
and each row represents the founder strain dosage for a given mouse. Residual heterozygosity is 
observed in some mice for this haplotype segment. Haplotype codes correspond to A/J  (A), 
C57BL/6J  (B), 129S1/SvImJ (C), NOD/LtJ (D),  NZO/HILtJ (E), CAST/EiJ (F), PWK/PhJ (G), and 
WSB/EiJ (H). 
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Figure 3.46.   Lung 625 ppm group hotspot haplotype dosages. Haplotype dosages at segment 
UNC23481318.UNC23486670 (chr13:118864010-119236105) for each mouse arranged by 
chromatin accessibility phenotype values at chromatin windows A) chr13:100123008-100123307 
and B) chr15:72891463-72891762. Each column corresponds to the phenotype value for a mouse, 
and each row represents the founder strain dosage for a given mouse. Residual heterozygosity is 
observed in some mice for this haplotype segment. Haplotype codes correspond to A/J  (A), 
C57BL/6J  (B), 129S1/SvImJ (C), NOD/LtJ (D),  NZO/HILtJ (E), CAST/EiJ (F), PWK/PhJ (G), and 
WSB/EiJ (H).
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Figure 3.47.   Genome-wide 625 ppm lung and kidney cQTL frequencies. Genome-wide view of 
the number of significant cQTLs (FDR 0.05) at each haplotype segment for A) lung and B) kidney. C) 
The number of significant distal cQTLs found in both lung and kidney in the 625 ppm group (FDR 
0.05) at each haplotype segment. 
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Figure 3.48.   Lung chr8 hotspot haplotype dosages. Haplotype dosages at segment 
JAX00663067 (chr8:23562597) for each mouse arranged by lung 625 ppm chromatin accessibility 
phenotype values at chromatin windows A) chr8:19981785-19982084 and B) chr8:197000103-
19700402. Each column corresponds to the phenotype value for a mouse, and each row represents 
the founder strain dosage for a given mouse. Residual heterozygosity is observed in some mice for 
this haplotype segment. Haplotype codes correspond to A/J  (A), C57BL/6J  (B), 129S1/SvImJ (C), 
NOD/LtJ (D),  NZO/HILtJ (E), CAST/EiJ (F), PWK/PhJ (G), and WSB/EiJ (H).
A 
B 
135 
 
 
Figure 3.49.   Kidney chr8 hotspot haplotype dosages. Haplotype dosages at segment 
JAX00663067 (chr8:23562597) for each mouse arranged by kidney 625 ppm chromatin 
accessibility phenotype values at chromatin windows A) chr8:19981785-19982084 and B) 
chr8:197000103-19700402. Each column corresponds to the phenotype value for a mouse, and 
each row represents the founder strain dosage for a given mouse. Residual heterozygosity is 
observed in some mice for this haplotype segment. Haplotype codes correspond to A/J  (A), 
C57BL/6J  (B), 129S1/SvImJ (C), NOD/LtJ (D),  NZO/HILtJ (E), CAST/EiJ (F), PWK/PhJ (G), and 
WSB/EiJ (H). 
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CC Strain Treatment 
Group 
Tissue RNA-seq ATAC-seq 
CC001 0 ppm Kidney yes yes 
CC001 0 ppm Liver yes yes 
CC001 0 ppm Lung yes yes 
CC001 1500 ppm Kidney yes no 
CC001 1500 ppm Liver yes no 
CC001 1500 ppm Lung yes no 
CC001 625 ppm Kidney yes yes 
CC001 625 ppm Liver yes yes 
CC001 625 ppm Lung yes yes 
CC002 0 ppm Kidney yes yes 
CC002 0 ppm Liver yes yes 
CC002 0 ppm Lung yes yes 
CC002 1500 ppm Kidney yes no 
CC002 1500 ppm Liver yes no 
CC002 1500 ppm Lung yes no 
CC002 625 ppm Kidney yes yes 
CC002 625 ppm Liver yes yes 
CC002 625 ppm Lung yes yes 
CC003 0 ppm Kidney yes yes 
CC003 0 ppm Liver yes yes 
CC003 0 ppm Lung yes yes 
CC003 1500 ppm Kidney yes no 
CC003 1500 ppm Liver yes no 
CC003 1500 ppm Lung yes no 
CC003 625 ppm Kidney yes yes 
CC003 625 ppm Liver yes yes 
CC003 625 ppm Lung yes yes 
CC004 0 ppm Kidney yes yes 
CC004 0 ppm Liver yes yes 
CC004 0 ppm Lung yes yes 
CC004 1500 ppm Kidney yes no 
CC004 1500 ppm Liver yes no 
CC004 1500 ppm Lung yes no 
CC004 625 ppm Kidney yes yes 
CC004 625 ppm Liver yes yes 
CC004 625 ppm Lung yes yes 
CC005 0 ppm Kidney yes yes 
CC005 0 ppm Liver yes yes 
CC005 0 ppm Lung yes yes 
CC005 1500 ppm Kidney yes no 
CC005 1500 ppm Liver yes no 
CC005 1500 ppm Lung yes no 
CC006 0 ppm Kidney yes yes 
CC006 0 ppm Liver yes yes 
CC006 0 ppm Lung yes yes 
CC006 625 ppm Kidney yes yes 
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CC006 625 ppm Liver yes yes 
CC006 625 ppm Lung yes yes 
CC007 0 ppm Kidney yes yes 
CC007 0 ppm Liver yes yes 
CC007 0 ppm Lung yes yes 
CC007 1500 ppm Kidney yes no 
CC007 1500 ppm Liver yes no 
CC007 1500 ppm Lung yes no 
CC010 0 ppm Kidney yes yes 
CC010 0 ppm Liver yes yes 
CC010 0 ppm Lung yes yes 
CC010 1500 ppm Kidney yes no 
CC010 1500 ppm Liver yes no 
CC010 1500 ppm Lung yes no 
CC010 625 ppm Kidney yes yes 
CC010 625 ppm Liver yes yes 
CC010 625 ppm Lung yes yes 
CC011 0 ppm Kidney yes yes 
CC011 0 ppm Liver yes yes 
CC011 0 ppm Lung yes yes 
CC011 1500 ppm Kidney yes no 
CC011 1500 ppm Liver yes no 
CC011 1500 ppm Lung yes no 
CC012 0 ppm Kidney yes yes 
CC012 0 ppm Liver yes yes 
CC012 0 ppm Lung yes yes 
CC012 1500 ppm Kidney yes no 
CC012 1500 ppm Liver yes no 
CC012 1500 ppm Lung yes no 
CC012 625 ppm Kidney yes yes 
CC012 625 ppm Liver yes yes 
CC012 625 ppm Lung yes yes 
CC013 0 ppm Kidney yes yes 
CC013 0 ppm Liver yes yes 
CC013 0 ppm Lung yes yes 
CC013 1500 ppm Kidney yes no 
CC013 1500 ppm Liver yes no 
CC013 1500 ppm Lung yes no 
CC013 625 ppm Kidney yes yes 
CC013 625 ppm Liver yes yes 
CC013 625 ppm Lung yes yes 
CC015 0 ppm Kidney yes yes 
CC015 0 ppm Liver yes yes 
CC015 0 ppm Lung yes yes 
CC015 1500 ppm Kidney yes no 
CC015 1500 ppm Liver yes no 
CC015 1500 ppm Lung yes no 
CC015 625 ppm Kidney yes yes 
CC015 625 ppm Liver yes yes 
CC015 625 ppm Lung yes yes 
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CC016 0 ppm Kidney yes yes 
CC016 0 ppm Liver yes yes 
CC016 0 ppm Lung yes yes 
CC016 1500 ppm Kidney yes no 
CC016 1500 ppm Liver yes no 
CC016 1500 ppm Lung yes no 
CC016 625 ppm Kidney yes yes 
CC016 625 ppm Liver yes yes 
CC016 625 ppm Lung yes yes 
CC017 0 ppm Kidney yes yes 
CC017 0 ppm Liver yes yes 
CC017 0 ppm Lung yes yes 
CC017 1500 ppm Kidney yes no 
CC017 1500 ppm Liver yes no 
CC017 1500 ppm Lung yes no 
CC017 625 ppm Kidney yes yes 
CC017 625 ppm Liver yes yes 
CC017 625 ppm Lung yes yes 
CC018 0 ppm Kidney yes yes 
CC018 0 ppm Liver no no 
CC018 0 ppm Lung yes yes 
CC018 1500 ppm Kidney yes no 
CC018 1500 ppm Liver yes no 
CC018 1500 ppm Lung yes no 
CC018 625 ppm Kidney yes yes 
CC018 625 ppm Liver yes yes 
CC018 625 ppm Lung yes yes 
CC019 0 ppm Kidney yes yes 
CC019 0 ppm Liver yes yes 
CC019 0 ppm Lung yes yes 
CC019 1500 ppm Kidney yes no 
CC019 1500 ppm Liver yes no 
CC019 1500 ppm Lung yes no 
CC019 625 ppm Kidney yes yes 
CC019 625 ppm Liver yes yes 
CC019 625 ppm Lung yes yes 
CC020 0 ppm Kidney yes yes 
CC020 0 ppm Liver yes yes 
CC020 0 ppm Lung yes yes 
CC020 1500 ppm Kidney yes no 
CC020 1500 ppm Liver yes no 
CC020 1500 ppm Lung yes no 
CC020 625 ppm Kidney yes yes 
CC020 625 ppm Liver yes yes 
CC020 625 ppm Lung yes yes 
CC021 0 ppm Kidney yes yes 
CC021 0 ppm Liver yes yes 
CC021 0 ppm Lung yes yes 
CC021 625 ppm Kidney yes yes 
CC021 625 ppm Liver yes yes 
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CC021 625 ppm Lung yes yes 
CC023 0 ppm Kidney yes yes 
CC023 0 ppm Liver yes yes 
CC023 0 ppm Lung yes yes 
CC023 1500 ppm Kidney yes no 
CC023 1500 ppm Liver yes no 
CC023 1500 ppm Lung yes no 
CC023 625 ppm Kidney yes yes 
CC023 625 ppm Liver yes yes 
CC023 625 ppm Lung yes yes 
CC024 0 ppm Kidney yes yes 
CC024 0 ppm Liver yes yes 
CC024 0 ppm Lung yes yes 
CC024 1500 ppm Kidney yes no 
CC024 1500 ppm Liver yes no 
CC024 1500 ppm Lung yes no 
CC024 625 ppm Kidney yes yes 
CC024 625 ppm Liver yes yes 
CC024 625 ppm Lung yes yes 
CC025 0 ppm Kidney yes yes 
CC025 0 ppm Liver yes yes 
CC025 0 ppm Lung yes yes 
CC025 625 ppm Kidney yes yes 
CC025 625 ppm Liver yes yes 
CC025 625 ppm Lung yes yes 
CC027 0 ppm Kidney yes yes 
CC027 0 ppm Liver yes yes 
CC027 0 ppm Lung yes yes 
CC027 1500 ppm Kidney yes no 
CC027 1500 ppm Liver yes no 
CC027 1500 ppm Lung yes no 
CC027 625 ppm Kidney yes yes 
CC027 625 ppm Liver yes yes 
CC027 625 ppm Lung yes yes 
CC028 0 ppm Kidney yes yes 
CC028 0 ppm Liver yes yes 
CC028 0 ppm Lung yes yes 
CC028 1500 ppm Kidney yes no 
CC028 1500 ppm Liver yes no 
CC028 1500 ppm Lung yes no 
CC028 625 ppm Kidney yes yes 
CC028 625 ppm Liver yes yes 
CC028 625 ppm Lung yes yes 
CC029 0 ppm Kidney yes yes 
CC029 0 ppm Liver yes yes 
CC029 0 ppm Lung yes yes 
CC029 1500 ppm Kidney yes no 
CC029 1500 ppm Liver yes no 
CC029 1500 ppm Lung yes no 
CC029 625 ppm Kidney yes yes 
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CC029 625 ppm Liver yes yes 
CC029 625 ppm Lung yes yes 
CC030 0 ppm Kidney yes yes 
CC030 0 ppm Liver yes yes 
CC030 0 ppm Lung yes yes 
CC030 1500 ppm Kidney yes no 
CC030 1500 ppm Liver yes no 
CC030 1500 ppm Lung yes no 
CC030 625 ppm Kidney yes yes 
CC030 625 ppm Liver yes yes 
CC030 625 ppm Lung yes yes 
CC031 0 ppm Kidney yes yes 
CC031 0 ppm Liver yes yes 
CC031 0 ppm Lung yes yes 
CC031 1500 ppm Kidney yes no 
CC031 1500 ppm Liver yes no 
CC031 1500 ppm Lung yes no 
CC031 625 ppm Kidney yes yes 
CC031 625 ppm Liver yes yes 
CC031 625 ppm Lung yes yes 
CC032 0 ppm Kidney yes yes 
CC032 0 ppm Liver yes yes 
CC032 0 ppm Lung yes yes 
CC032 1500 ppm Kidney yes no 
CC032 1500 ppm Liver yes no 
CC032 1500 ppm Lung yes no 
CC033 0 ppm Kidney yes yes 
CC033 0 ppm Liver yes yes 
CC033 0 ppm Lung yes yes 
CC033 1500 ppm Kidney yes no 
CC033 1500 ppm Liver yes no 
CC033 1500 ppm Lung yes no 
CC033 625 ppm Kidney yes yes 
CC033 625 ppm Liver yes yes 
CC033 625 ppm Lung yes yes 
CC035 0 ppm Kidney yes yes 
CC035 0 ppm Liver yes yes 
CC035 0 ppm Lung yes yes 
CC035 1500 ppm Kidney yes no 
CC035 1500 ppm Liver yes no 
CC035 1500 ppm Lung yes no 
CC035 625 ppm Kidney yes yes 
CC035 625 ppm Liver yes yes 
CC035 625 ppm Lung yes yes 
CC036 0 ppm Kidney yes yes 
CC036 0 ppm Liver yes yes 
CC036 0 ppm Lung yes yes 
CC036 1500 ppm Kidney yes no 
CC036 1500 ppm Liver yes no 
CC036 1500 ppm Lung yes no 
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CC036 625 ppm Kidney yes yes 
CC036 625 ppm Liver yes yes 
CC036 625 ppm Lung yes yes 
CC037 0 ppm Kidney yes yes 
CC037 0 ppm Liver yes yes 
CC037 0 ppm Lung yes yes 
CC037 1500 ppm Kidney yes no 
CC037 1500 ppm Liver yes no 
CC037 1500 ppm Lung yes no 
CC037 625 ppm Kidney yes yes 
CC037 625 ppm Liver yes yes 
CC037 625 ppm Lung yes yes 
CC038 0 ppm Kidney yes yes 
CC038 0 ppm Liver yes yes 
CC038 0 ppm Lung yes yes 
CC038 1500 ppm Kidney yes no 
CC038 1500 ppm Liver yes no 
CC038 1500 ppm Lung yes no 
CC038 625 ppm Kidney yes yes 
CC038 625 ppm Liver yes yes 
CC038 625 ppm Lung yes yes 
CC039 0 ppm Kidney yes yes 
CC039 0 ppm Liver yes yes 
CC039 0 ppm Lung yes yes 
CC039 1500 ppm Kidney yes no 
CC039 1500 ppm Liver yes no 
CC039 1500 ppm Lung yes no 
CC039 625 ppm Kidney yes yes 
CC039 625 ppm Liver yes yes 
CC039 625 ppm Lung yes yes 
CC040 0 ppm Kidney yes yes 
CC040 0 ppm Liver yes yes 
CC040 0 ppm Lung yes yes 
CC040 1500 ppm Kidney yes no 
CC040 1500 ppm Liver yes no 
CC040 1500 ppm Lung yes no 
CC040 625 ppm Kidney yes yes 
CC040 625 ppm Liver yes yes 
CC040 625 ppm Lung yes yes 
CC041 0 ppm Kidney yes yes 
CC041 0 ppm Liver yes yes 
CC041 0 ppm Lung yes yes 
CC041 1500 ppm Kidney yes no 
CC041 1500 ppm Liver yes no 
CC041 1500 ppm Lung yes no 
CC042 0 ppm Kidney yes yes 
CC042 0 ppm Liver yes yes 
CC042 0 ppm Lung yes yes 
CC042 1500 ppm Kidney yes no 
CC042 1500 ppm Liver yes no 
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CC042 1500 ppm Lung yes no 
CC042 625 ppm Kidney yes yes 
CC042 625 ppm Liver yes yes 
CC042 625 ppm Lung yes yes 
CC043 0 ppm Kidney yes yes 
CC043 0 ppm Liver yes yes 
CC043 0 ppm Lung yes yes 
CC043 625 ppm Kidney yes yes 
CC043 625 ppm Liver yes yes 
CC043 625 ppm Lung yes yes 
CC044 0 ppm Kidney yes yes 
CC044 0 ppm Liver yes yes 
CC044 0 ppm Lung yes yes 
CC044 1500 ppm Kidney yes no 
CC044 1500 ppm Liver yes no 
CC044 1500 ppm Lung yes no 
CC044 625 ppm Kidney yes yes 
CC044 625 ppm Liver yes yes 
CC044 625 ppm Lung yes yes 
CC045 0 ppm Kidney yes yes 
CC045 0 ppm Liver yes yes 
CC045 0 ppm Lung yes yes 
CC045 625 ppm Kidney yes yes 
CC045 625 ppm Liver yes yes 
CC045 625 ppm Lung yes yes 
CC046 0 ppm Kidney yes yes 
CC046 0 ppm Liver yes yes 
CC046 0 ppm Lung yes yes 
CC046 1500 ppm Kidney yes no 
CC046 1500 ppm Liver yes no 
CC046 1500 ppm Lung yes no 
CC049 0 ppm Kidney yes yes 
CC049 0 ppm Liver yes yes 
CC049 0 ppm Lung yes yes 
CC049 1500 ppm Kidney yes no 
CC049 1500 ppm Liver yes no 
CC049 1500 ppm Lung yes no 
CC049 625 ppm Kidney yes yes 
CC049 625 ppm Liver yes yes 
CC049 625 ppm Lung yes yes 
CC051 0 ppm Kidney no no 
CC051 0 ppm Liver yes yes 
CC051 0 ppm Lung yes yes 
CC051 1500 ppm Kidney yes no 
CC051 1500 ppm Liver yes no 
CC051 1500 ppm Lung yes no 
CC051 625 ppm Kidney yes yes 
CC051 625 ppm Liver yes yes 
CC051 625 ppm Lung yes yes 
CC053 0 ppm Kidney yes yes 
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CC053 0 ppm Liver yes yes 
CC053 0 ppm Lung yes yes 
CC053 1500 ppm Kidney yes no 
CC053 1500 ppm Liver yes no 
CC053 1500 ppm Lung yes no 
CC053 625 ppm Kidney yes yes 
CC053 625 ppm Liver yes yes 
CC053 625 ppm Lung yes yes 
CC055 0 ppm Kidney yes yes 
CC055 0 ppm Liver yes yes 
CC055 0 ppm Lung yes yes 
CC055 1500 ppm Kidney yes no 
CC055 1500 ppm Liver yes no 
CC055 1500 ppm Lung yes no 
CC055 625 ppm Kidney yes yes 
CC055 625 ppm Liver yes yes 
CC055 625 ppm Lung yes yes 
CC057 0 ppm Kidney yes yes 
CC057 0 ppm Liver yes yes 
CC057 0 ppm Lung yes yes 
CC057 1500 ppm Kidney yes no 
CC057 1500 ppm Liver yes no 
CC057 1500 ppm Lung yes no 
CC057 625 ppm Kidney yes yes 
CC057 625 ppm Liver yes yes 
CC057 625 ppm Lung yes yes 
CC059 0 ppm Kidney yes yes 
CC059 0 ppm Liver yes yes 
CC059 0 ppm Lung yes yes 
CC060 1500 ppm Kidney yes no 
CC060 1500 ppm Liver yes no 
CC060 1500 ppm Lung yes no 
CC060 625 ppm Kidney yes yes 
CC060 625 ppm Liver yes yes 
CC060 625 ppm Lung yes yes 
CC061 0 ppm Kidney yes yes 
CC061 0 ppm Liver yes yes 
CC061 0 ppm Lung yes yes 
CC061 1500 ppm Kidney yes no 
CC061 1500 ppm Liver yes no 
CC061 1500 ppm Lung yes no 
CC061 625 ppm Kidney yes yes 
CC061 625 ppm Liver yes yes 
CC061 625 ppm Lung yes yes 
CC062 0 ppm Kidney yes yes 
CC062 0 ppm Liver yes yes 
CC062 0 ppm Lung yes yes 
CC062 1500 ppm Kidney yes no 
CC062 1500 ppm Liver yes no 
CC062 1500 ppm Lung yes no 
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CC062 625 ppm Kidney yes yes 
CC062 625 ppm Liver yes yes 
CC062 625 ppm Lung yes yes 
CC068 0 ppm Kidney yes yes 
CC068 0 ppm Liver yes yes 
CC068 0 ppm Lung yes yes 
CC068 1500 ppm Kidney yes no 
CC068 1500 ppm Liver yes no 
CC068 1500 ppm Lung yes no 
CC068 625 ppm Kidney yes yes 
CC068 625 ppm Liver yes yes 
CC068 625 ppm Lung yes yes 
 
Table 3.1.   Inventory of CC mouse samples. CC strains represented in each tissue and treatment 
group and whether RNA-seq and ATAC-seq data were processed for these strains. 
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Tissue and 
Treatment Group 
Total 
Genes 
Tested 
Total eQTLs 
(FDR 0.05) 
eGenes 
Detected 
(FDR 0.05) 
eGenes with 
Local 
Associations 
(FDR 0.05) 
eGenes with 
Distal 
Associations 
(FDR 0.05) 
Lung – Control 17,675 400 67 34 36 
Lung – 625 ppm 17,536 505 97 58 44 
Lung – 1500 ppm 17,376 869 114 66 55 
Liver – Control 13,629 1,368 168 101 82 
Liver – 625 ppm 13,355 842 102 44 65 
Liver – 1500 ppm 13,299 1,803 216 128 104 
Kidney – Control 15,894 1,718 213 105 124 
Kidney – 625 ppm 15,625 2,336 283 162 136 
Kidney – 1500 ppm 15,408 3,523 417 255 188 
 
Table 3.2.   eQTL mapping results overview. Summary of eQTL mapping results in each tissue 
and treatment group. The term “eGenes” denotes an eQTL gene with at least one significantly 
associated segment. 
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Tissue and 
Treatment Group 
Total 
Chromatin 
Windows 
Tested 
Total cQTLs 
(FDR 0.05) 
Unique 
cQTL 
Chromatin 
Windows  
(FDR 0.05) 
cQTL Chromatin 
Windows with 
Local 
Associations 
(FDR 0.05) 
cQTL Chromatin 
Windows with 
Distal 
Associations 
(FDR 0.05) 
Lung – Control 24,949 3,328 325 72 256 
Lung – 625 ppm 24,666 8,472 594 93 510 
Liver – Control 25,762 88 15 7 11 
Liver – 625 ppm 25,785 0 0 0 0 
Kidney – Control 25,081 5,700 353 105 257 
Kidney – 625 ppm 25,280 2,532 238 87 164 
 
Table 3.3.   cQTL mapping results overview. Summary of cQTL mapping results in each tissue 
and treatment group. 
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CHAPTER IV 
Discussion 
 
Current technologies allow for researchers to employ a broad array of high-throughput 
methods to produce data related to many facets of gene regulation such as chromatin organization 
and interaction, DNA methylation, histone modifications, TF occupancy, microRNA expression, and 
gene expression. Studies have integrated these data types to elucidate the details of gene regulation, 
and in doing so provided insight into the variability in how these regulatory components present 
and interact between different cell types, tissues, and conditions. Furthermore, studies assessing 
the contributions of genetic variation on these gene regulatory properties have demonstrated 
regulatory variability due to genetic differences between individuals. With such an elaborate 
picture of the factors contributing to understanding context-specific gene regulation, much still 
needs to be learned about the biology as well as how to devise analyses that best take advantage of 
the data. 
In chapter II, I provided an overview of footprinting and assessed currently held 
assumptions about TF footprints. Using ENCODE ChIP-seq and DNase-seq data in conjunction with 
TF motif site predictions, I showed that DNase-seq signals at active and inactive motif sites are 
more heterogeneous than previously assumed, violating assumptions many current footprinters 
use when identifying TFBSs. To address this heterogeneity, I introduced DeFCoM, a novel machine 
learning framework for predicting TFBSs using DNase-seq data. DeFCoM applied a supervised 
learning approach to classification in order to learn the characteristics of footprints as opposed to 
enforcing assumptions about their structure. Through a comprehensive comparison with 9 other 
footprinters using 71 test sets for 18 TFs, I showed that DeFCoM performed the best overall. 
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Furthermore, by assessing footprintability at varying sequencing depths and using data sets of 
different signal quality, I observed that footprintability varied drastically by TF. Intuitively, 
sequencing depth and data set signal quality should improve footprintability, but the degree of 
benefit for both are also TF dependent. In addition, I applied DeFCoM to ATAC-seq GM12878 data 
and noted similar but slightly decreased performance relative to using DNase-seq GM12878 data, 
though this may be attributable to differences in sequencing depth and signal-to-noise.  
As an area of research, genomic footprinting is still maturing. The first genome-wide 
footprinting paper was published in 2009, and it reported the detection of footprints in the 
Saccharomyces cerevisiae genome [44]. Despite the lack of a comprehensive understanding of 
footprint characteristics, papers have been published that include extensive analyses of TF 
dynamics and networks for numerous cell types and across species based solely on computational 
footprint predictions [101,102] using a method that performed poorly in my footprinter 
comparisons. The conclusions drawn solely from footprinting raised concerns that were voiced in 
[103]. To appropriately make use of footprinting, DNase-seq and ATAC-seq signal at TFBSs need to 
be better characterized. My work in chapter II contributes to the need for better footprint 
characterization by highlighting the degree of footprint heterogeneity and showing the impact of 
sequencing depth and signal quality on footprintability. This research further expands the field by 
demonstrating a motif-centric approach to assessing footprint predication accuracy and using a 
single, unified framework to evaluate most currently existing footprinters. 
Looking towards future research in genomic footprinting, a priority needs to be placed on 
further characterizing the biological and technical factors impacting TF footprint profiles. Currently, 
annotating TFBSs for footprinting studies relies predominately on ChIP-seq data, but the literature 
remains scarce in regards to how an imperfect concordance between ChIP-seq based annotations 
and TF footprints impacts footprint characterization and prediction. For elucidating properties of 
footprint profiles, more refined and accurate TFBS annotations would produce more robust 
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characterizations. An improved understanding of footprint signals in chromatin accessibility data 
would allow for more refined and appropriate statistical models and machine learning methods to 
be implemented for footprint classification. As footprint characterization improves and quantitative 
models become more accurate, footprinting offers promising new avenues for investigating TF 
binding. In the context of differential chromatin accessibility studies, DNase-seq and ATAC-seq 
could be utilized more effectively to identify differential TF binding through evaluating changes in 
chromatin accessibility signal at TFBSs.  Accurate identification of differential TF binding with 
chromatin accessibility assays would offer an alternative option to ChIP-seq for genome-wide 
studies. ATAC-seq and DNase-seq would capture binding events for many TFs within a single 
experiment as opposed to ChIP-seq which assays one TF per experiment. Another exciting avenue 
for genomic footprinting research lies in pairing genotype information with accurate quantification 
of footprint changes. In genomics studies where genotype and chromatin accessibility data are 
available, footprint variability could be defined as a quantitative trait and tested for associations 
with genetic variability using QTL mapping approaches. These analyses would help clarify TF 
binding and the gene regulatory mechanisms influenced by genetic variability within a given 
context. 
 In chapter III, I used liver, lung, and kidney ATAC-seq and RNA-seq data for CC mice from 
three different BD treatment groups (control, 625 ppm exposure, and 1500 ppm exposre) to assess 
the impact of BD exposure on gene expression and chromatin accessibility. From PCA of the 
samples, I observed that tissue differences accounted for more variability than BD exposure in both 
gene expression and chromatin accessibility. Further analyses revealed that in both gene 
expression and chromatin accessibility, lung and liver exhibited more pronounced changes than 
kidney. This result complements a previous study in which DNA methylation and histone 
modifications were shown to significantly change at the global level for lung and liver but not 
kidney tissue in C57BL6/J mice [69]. My analyses build upon these observations by showing a 
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similar affect for chromatin accessibility and gene expression using mice with diverse genetic 
backgrounds. Since the ATAC-seq and RNA-seq data provide genome-wide information, these data 
can be further examined to identify specific regulatory elements and genes that are driving the 
tissue-specific differences to BD exposure.  
In addition to the global variation assessments, I also provide a characterization of eQTLs 
and cQTLs in each of the tissues and treatment groups. In general, I observed eQTLs and cQTLs to 
be more consistent within a tissue and across treatment groups than within a treatment group and 
across tissues. Additionally, of the 3 tissues, I observed lung eQTLs to be the least concordant across 
treatment groups suggesting that the BD response in lung is causing unique gene expression 
changes that are also associated with genetic variation. For the cQTL analysis, I discovered 
previously uncharacterized cQTL hotspots in lung and kidney and identified potential causal 
founder haplotypes driving these hotspots. From these observations, the dynamic changes in lung 
and its significance in BD metabolism suggest that it should be prioritized in future analyses. To my 
knowledge, this cQTL characterization study is the first to be done for a mouse population, but both 
the eQTL and cQTL analyses leave many questions to be answered in regards to better 
understanding the genetic underpinnings of BD response. In [35], CC mice liver eQTLs were 
mapped using a “delta” phenotype model. Because CC strains are inbred, mice from the same strain 
can be subject to two different conditions, and the difference or ratio between measurements of 
gene expression can be used as the phenotype. With the CC population the genetic diversity 
between strains allows for this delta phenotype to be incorporated into eQTL mapping. For future 
work, this approach can be taken with the BD data to infer more direct relationships between 
genetics, chromatin accessibility, gene expression, and BD exposure. The ability to take advantage 
of such a model demonstrates the utility of the CC, in conjunction with sequencing-based assays of 
gene regulation and gene expression, in elucidating the gene regulatory architecture underlying 
toxic chemical exposure. 
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As genomic footprinting improves, TF binding dynamics can be incorporated into studies 
akin to the work described in chapter III. This experimental design would be able to integrate 
genotype, gene expression, chromatin accessibility, TF occupancy, and an environmental 
perturbation to paint a more comprehensive picture of context-specific gene regulation. 
Incorporating additional data types such as microRNA expression and 3D chromatin interactions 
among others would offer even greater explanatory power. With our current understanding of the 
complexity of gene regulation, such integrative approaches will be necessary to deduce the 
underlying mechanistic links between genetics and complex traits. 
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